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The unstable expansion of the polyglutamine (polyQ) tract is a critical factor in the 
pathogenic pathway of at least ten neurodegenerative diseases, including Huntington’s 
disease, spinal and bulbar muscular atrophy (SBMA), dentatorubral-pallidoluysian atrophy 
(DRPLA), and seven spinocerebellar ataxias, all of which are termed as polyglutamine 
diseases. One less understood but common feature of polyQ diseases is polyQ protein 
aggregation. This dissertation explores the protein folding, hydrogen bonding, and water 
accessibility changes which are induced by the enlargement of the polyQ tract using 
advanced informatics and computational methods, including protein 3D structure modeling 
and molecular dynamics simulations. This dissertation also demonstrates that these state-
of-the-art computational and informatics methods are powerful tools to provide useful 
insights into protein aggregation in polyQ diseases. 
The enlargement of polyQ segments affects both local and global structures of polyQ 
proteins as well as their water-accessibility, hydrogen bond patterns, and other structural 
characteristics. Results from both isolated polyQ and polyQ segments in the context of 
ataxin-2 and ataxin-3 show that the polyQ tracts increasingly prefer self-interaction as the 
lengths of the tracts increase, indicating an increased tendency toward aggregation among 
larger polyQ tracts. These results provide new insights into possible pathogenic 
mechanisms of polyQ diseases based solely on the increased propensity toward polyQ 




therapeutic strategy for treating polyQ diseases. 
The analysis pipeline designed and used in this study is an effective way to study the 
molecular mechanism of polyQ diseases, and can be generalized to study other diseases 
associated with the protein conformation changes, such as Parkinson’s disease, 
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INTRODUCTION AND BACKGROUND 
 
 
The unstable expansion of the cytosine-adenine-guanine (CAG) repeat in the coding 
regions of several genes is associated with at least ten neurodegenerative diseases. These 
diseases are termed polyglutamine (polyQ) diseases as the CAG repeats are translated into 
polyglutamine in the related proteins. Although the genes related to each polyQ disease 
were discovered in the early 20th century the pathogenesis mechanism of these diseases is 
still not well understood. As a result, there is no curative treatment available. The polyQ 
tract expansion is the only common feature shared by the ten polyQ diseases and has long 
been considered a key factor in their pathogenic pathway. The expanded polyQ tract can 
trigger protein misfolding and aggregation which can result in neuron dysfunction. Using 
advanced informatics and computational methods, this dissertation studies the folding, 
hydrogen bonding, and water accessibility properties of the polyQ tract – within and 
without the context of polyQ proteins – to understand, at the molecular level, the 




PolyQ diseases are a family of neurodegenerative disorders associated with the 
expansion of CAG repeats in a specific gene [1, 2], in which the CAG repeats are translated 




these diseases are Huntington’s disease (HD) [3], dentatorubral-pallidoluysian atrophy 
(DRPLA) [4], spinal and bulbar muscular atrophy (SBMA) [5], and spinocerebellar ataxias 
(SCA) type 1, 2, 3, 6, 7, 8, 17 [6-9]. The polyQ genes express in both patients and normal 
individuals, but only individuals with a CAG repeat number larger than certain thresholds 
develop the disease [1]. In addition, the CAG repeat expansion in the ATXN8 gene is 
related to SCA8 and the pathogenesis of SCA8 also involves the noncoding gene 
ATXN8OS, with a CTG repeat [10].  
PolyQ diseases are relatively rare, and the prevalence of each disorder can vary with 
geographic location and ethnic background. The estimated prevalence of HD is 2.7 per 
100,000 worldwide. Meta-analysis shows a higher prevalence of HD in Europe, North 
America, and Australia (5.7 per 100,000) than it does in Asia (0.40 per 100,000) [11]. The 
prevalence of SCA, as a whole, is similar to HD and is estimated to be 2-3 per 100,000 
[12], but the frequency can vary with different ethnic groups [13]. SCA3 is the most 
common spinocerebellar ataxia followed by SCA2, SCA1 and SCA8 [12]. 
PolyQ diseases share common pathogenic characteristics despite the different affected 
genes. They are all neurodegenerative diseases characterized by a progressive degeneration 
of neurons [4]. The number of CAG repeats is related to how quickly the diseases progress, 
with longer repeats exhibiting earlier and more severe symptoms than those seen in 
individual with smaller number of repeats. All polyQ diseases, except for SBMA, are 
autosomal dominant inherited diseases, which means one copy of abnormal CAG repeat 
genes in each cell is sufficient to cause the disease. Most polyQ disease patients are 
heterogeneous genotype with only one abnormal copy in the cell [14]. Evidence shows that 




only one mutant copy [15]. SBMA is X-linked because the CAG-repeat gene, Androgen 
Receptor (AR), is located in the X chromosome [5]. In males, who have only one copy of 
the X chromosome, the mutation in this chromosome can cause SBMA. Yet, the specific 
mechanism leading to neuronal dysfunctions related to polyQ diseases are not well 
understood [6].  
PolyQ disease includes a group of neurodegenerative diseases that display clinical and 
neuropathological heterogeneity, but a common feature shared by these disorders is the 
degeneration of a population of neurons in the central nervous system (CNS) [16-18]. The 
group of disorders has a broad impact on a person's functional abilities in motor [13, 18], 
and some subtypes might involve cognitive and psychiatric disorders [13]. For some polyQ 
disease subtypes, the patients may show symptoms of other neurodegenerative diseases, 
such as Parkinson’s diseases [16, 17] and Amyotrophic Lateral Sclerosis (ALS) [19]. 
Ataxia is a predominant clinical feature in SCA patients [18], and speech and swallowing 
are often affected in these patients [18, 20].  
Medical diagnoses of polyQ diseases can be made following the appearance of clinical 
symptoms specific to the diseases. Physical exam, family history, spinal tap, and magnetic 
resonance imaging (MRI) scanning of the brain and spine are usually included in the 
diagnosis procedures. Genetic tests detecting the number of CAG repeats in the defective 
genes can be used to confirm the diagnosis, as similar symptoms are shared among polyQ 
diseases [13]. 
PolyQ diseases are fatal and devastating diseases [21, 22] with no curative and/or 
disease-modifying treatment available [13, 18, 23]. After the onset of the disease, patients’ 




the duration of the disease may vary, but the time from disease onset to death is often about 
10 to 30 years [18]. The longer the repeat, the faster the disease progresses [25]. Juvenile 
Huntington’s disease, early-onset form of Huntington’s disease that begins in childhood or 
adolescence, usually results in death within 10 years as the CAG segment in HD gene can 
repeat more than 60 times in these patients [26]. Eventually, patients with polyQ diseases 
need help with daily living activities and care [27, 28]. To date, there are no curative 
treatments for polyQ diseases [13, 18, 23]. Medications are available to help manage the 
symptoms of the disease, but cannot prevent the physical, mental, and behavioral decline 
associated with the conditions [29]. An accurate diagnosis of a specific subtype of polyQ 
disease, especially through a genetic test, can provide great value for making a treatment 
and care plan [30].   
 
Polyglutamine Disease Related Genes and Proteins 
 
The genetic causes of polyQ diseases were discovered in the 1990’s. The expansion of 
CAG repeats in AR genes was identified as a possible cause of SBMA in 1991, making 
SBMA the first genetic disorder identified as part of the polyQ neurodegenerative disease 
group [5]. In 1993, a novel gene with the CAG trinucleotide repeat pattern, later called the 
HTT gene, was discovered within the HD chromosome, and the unstable expansion of 
CAG repeats was linked to Huntington’s disease [3]. In the same year, the CAG repeat 
expansion was discovered in the ATXN1 gene, which was directly related to SCA1 [31]. 
The CAG repeat expansion in six other genes, ATXN3 [6], ATN1 [4], ATXN2 [32], 
CACNA1A [33], ATXN7, and TBP [34], was identified in the 1990s and associated with 
these specific types of neurodegenerative diseases.  




(Table 1.1). Apart from the CAG repeat, they share little in gene size, gene sequence, and 
function, as do the related proteins. In regards to gene size, the huntingtin protein, which 
is associated with Huntington’s disease, can be as long as 3,144 amino acids, whereas the 
ataxin-3 protein and the TATA-box binding protein, which are associated with SCA3 and 
SCA17, respectively, are only around 300 amino acids in length. As regards gene sequence, 
the polyQ tracts lie in different regions of the polyQ proteins, but, in most cases, they are 
located close to the protein terminus. In addition to the differences in gene size and 
sequences, the functions of polyglutamine genes and related proteins also vary. The AR 
gene functions as a steroid-hormone activated transcription factor [35]. Ataxin-1, the 
protein translated from ATXN1, is reported to be involved in transcriptional repression and 
it is a component in the Notch signaling pathway [36]. Ataxin-2, the protein translated from 
ATXN2 gene, is part of the endocytic receptor cycling and affects EGF receptor trafficking 
[37]. Ataxin-3, the protein encoded by ATXN3, contains ubiquitin interaction motifs 
(UIM) and the Josehpin domain, and is involved in de-ubiquitination activity [38]. 
CACNA1A, the gene responsible for SCA6, is involved in voltage-gated calcium channels 
and mediates a number of calcium-dependent processes [39]. The function of huntingtin 
protein is still unclear [40, 41], but evidence shows that normal huntingtin is important for 
neuronal function [42]. Most of the polyQ proteins related to polyQ diseases can bind to a 
wide range of molecules, which bindings have been identified in a great number of studies. 
However, the exact function of the polyQ genes and proteins are still poorly understood.  
 
PolyQ Length Dependent Pathogenesis  
 
The number of CAG/polyQ repeats is a key factor for the progression of polyQ diseases 










Table 1.1 Polyglutamine diseases related genes and proteins 
 
 










SCA1 ATXN1 6p23 815 N-terminus  6-39 41-83 
SCA2 ATXN2 12q24.1 1313 N-terminus 13-31 >=32 
SCA3 ATXN3 14q21 364 C-terminus 12-43 60-89 
SCA6 CACNA1A 19p13 2512 C-terminus <18 20-33 
SCA7 ATXN7 3p21.1-p12 982 N-terminus <19 36-460 
SCA17 TBP 6q27 339 N-terminus 25-42 49-66 
HD HTT 4p16.3 3144 N-terminus 6-34 >40 
DRPLA ATN1 12p13.31 1190 N-terminus 6-35 >48 






value [1, 17] (Table 1.1). Although it varies, the threshold of most of these diseases is 
between 32 to 40 repeats [45], except for SCA6 which has a small threshold of around 20 
repeats [33]. A larger number of repeats is usually associated with an earlier onset of 
symptoms [46]. The expanded CAG segments are unstable [47] which can lead to an 
increase in repeats in successive generations. [48]. This phenomenon is known as genetic 
anticipation, and leads to an increase in disease severity and an early age of onset [48, 12, 
49, 50]. The average age of onset is in the adult years among patients with polyQ diseases 
[49, 39, 51], but individuals with extremely long repeats may show symptoms at very 
young age [49, 39, 51, 48]. For instance, SCA2 patients with 32 or 33 repeats tend to show 
symptoms of SCA2 in late adulthood, whereas patients with more than 45 repeats usually 
have signs and symptoms by their teenage years [18]. 
There are still some unanswered but interesting questions about polyQ length 
dependent features in polyQ disease, such as why do symptoms only occur in patients 
carrying the protein in which the length of polyQ tract is above a threshold and why do 
longer lengths above these thresholds lead to an early age of onset and more severe 
symptoms? Although in vivo experimental studies yield evidence that short-repeated polyQ 
tracts may also aggregate [52], longer polyQ tracts provoke an earlier appearance of disease 
and faster progression [53]. One possible explanation is that the aggregation propensity of 
long polyQ tracts is higher than that of the short ones [53]. Therefore, people with 
short/normal repeats may not display symptoms during their lifetime. In some of the polyQ 
diseases, including Huntington’s disease, SCA1, SCA3, SCA7, SCA17, and SBMA, there 
exists the reduced-penetrance form of polyQ tracts, and individuals carrying the reduced-




the smallest repeats related to clinical symptoms is reported to vary from 36 to 40, while 
the upper range of normal repeats is reported from 30 to 39 repeats. The polyQ gene with 
36 to 39 repeats is reported as the reduced-penetrance allele.  
 
Protein Misfolding and Aggregation 
 
The most important feature shared by polyQ proteins is their propensity to form 
oligomers and aggregates. The intranuclear inclusion bodies are found in the affected 
neurons in almost all types of the polyQ diseases [54, 55, 49, 56-60], except for SCA2 [61, 
62] and SCA6 [63], in which the aggregations are found in the cytoplasm. However, the 
molecular mechanisms of polyQ protein aggregation remain unclear [2]. It is also unclear 
if aggregation is a cause of the polyQ diseases or a consequence of them, as neurological 
symptoms may show up before protein aggregation can be detected in several transgenic 
models [64]. Evidence also indicates that large visible inclusions may be protective by 
recruiting and enhancing the degradation of toxic polyQ proteins [65], whilst the oligomers 
or microaggregates might be the toxic formations [66].  
Evidence also indicates that the expanded polyQ tracts alter protein conformation [47], 
which could allow the mutant protein to recruit normal cellular proteins through a series of 
abnormal interactions. Some interactions can be enhanced, whereas others may be lost or 
remain unchanged [47]. For example, in the SCA1 transgenic mice model, ataxin-1 with 
expanded polyQ can alter the transcription of several genes, including genes involved in 
signal transduction and calcium homeostasis [67].  
In addition to the polyQ proteins, other proteins may be included in the aggregation to 
make large inclusions. A variety of glutamine-rich transcriptional regulators are known to 




aggregation could initiate cellular dysfunction by sequestering the respective proteins, both 
mutant polyQ proteins and other proteins, from their normal localization, causing 
imbalance of proteins in cells, and compromising their functions [2].  
Proteolysis cleavage is confirmed in several polyQ proteins, including ataxin-3 [68], 
huntingtin [69], atrophin-1 [70], and ataxin-7 [71]. These proteins can be degenerated by 
proteases into fragments. As shown in Table 1.1, polyQ repeats are, in general, located in 
either the N-terminus or the C-terminus of polyQ proteins, which location facilitates the 
release of polyQ fragments. Fragments containing polyQ tracts might display misfolded 
structures and cause the micro-aggregation of oligomers [1]. These aggregated oligomers 
may cause the dysfunction of related proteins and show toxicity properties to the cell 
environment, which have a potential role in polyQ disease pathogenesis. 
As aggregation is a hallmark of polyQ disease progression [72], the knowledge of 
aggregation mechanisms, at the molecular level, can provide new avenues to explore 
common therapeutic methods for treating these disorders. Also, as protein misfolding and 
aggregation are common features in other neurodegenerative disorders, such as 
Alzheimer’s disease, Parkinson’s disease, and ALS [73, 74], the knowledge of polyQ 
misfolding and aggregation identified here could also shed light on the pathogenic 
mechanism of other neurodegenerative diseases.  
 
Hydrophobicity and Water Accessibility  
 
Known intrinsic properties that can effect protein aggregation include charge, 
hydrophobic/hydrophilic patterns, and secondary structures [75]. Among these factors, 
hydrophobicity plays a significant role in setting the conditions governing protein 




As a polar region, polyQ segments have the propensity to aggregate, and in aqueous 
milieus, an individual polyQ peptide prefers collapsed structures that minimize interactions 
with a surrounding solvent [77]. Perutz [78] proposes that expansion of glutamine repeats 
beyond a certain length may lead to a phase change from random coils to hydrogen-bonded 
self-associated confirmations. Consistent with this hypothesis, both experimental and 
computational studies, show that polyQ tracts can change the conformation to hydrogen-
bonded structures during the formation of aggregation [79-83]. However, these hypotheses 
have not been verified by detailed 3D protein structure studies in the context of the full-
length polyQ proteins or by using full atomic explicit solvent molecular dynamics 
simulations. 
 
Conformational Study of PolyQ Containing Proteins 
 
The elongation of the polyQ tract can lead to misfolding of polyQ proteins, which 
affects the normal functions of these proteins [55]. Therefore, a knowledge of protein 
structure changes as the function of the lengthening of the polyQ tract can bring insights 
into the molecular mechanism of pathogenesis in polyQ diseases.  
However, due to the large protein size and aggregation property of polyQ proteins, it 
is difficult to obtain high-quality 3D structures of full-length polyQ proteins through 
experimental studies, such as X-ray and nuclear magnetic resonance spectroscopy (NMR). 
Until now, few 3D structures of polyQ protein are available in the Research Collaboratory 
for Structural Bioinformatics (RCSB) Protein Data Bank (PDB) [84], and none of these 
structures represent full-length polyQ proteins. Even fewer contain the polyQ tract in the 
structures. The only known structures of polyQ protein segments with polyQ tract are the 




[86]. There are several structures of polyQ protein segments with no polyQ tract, such as 
solution structures of the Josephin domain in ataxin-3 [87] and solution structures of the 
UIM domains of ataxin-3 complexed with ubiquitin [88]. With state-of-the-art 
experimental methods, such as circular dichroism (CD) and fluorescence spectroscopy, it 
is possible to measure changes in the surface exposure of polyQ proteins induced by polyQ 
tract expansion[89], but these techniques cannot provide information with enough detail to 
address the structural changes at the residue and atomic levels.  
By resolving the structure of a short polyQ monomer of 15Qs, Perutz puts forward the 
hypothesis that expanded polyQ tracts form misfolded structures which can lead to protein 
aggregation [90]. In Perutz’s theory, the elongated polyQ tract may form a “polar zipper” 
conformation, a structure with β-strands and an extensive hydrogen-bonded network [90]. 
The polar zipper structure is latter interpreted as the cross-beta structure. Perutz’s polyQ 
structure model led to a series of computational studies on the thermodynamic and kinetic 
characters of polyQ tracts. These computational studies yield several plausible structures 
for polyQ tracts [91, 80]. PolyQ with certain structures therefore can initialize the 
aggregation which leads to the formation of amyloid fibrils [53, 92]. Yet, the precise 
mechanism involved in polyQ aggregation is still largely unknown.   
 
Protein 3D Structure Prediction 
 
Protein 3D structure prediction is a set of computational techniques with the capability 
to infer the 3D models of a protein using its amino acid sequence [93]. Protein 3D structure 
prediction plays a critical role in biomedical research, as it is an essential tool to predict 
structures of biomedical molecules for which no experimental structures are yet obtainable. 




protein binding sites that can be used for in silico drug design [94, 95].  
The previous solved structures, or template, can be used in protein structure prediction. 
Based on whether templates are used or not, protein structure prediction methods can be 
divided into two categories: comparative protein modeling and ab initio modeling [96]. In 
comparative protein modeling, templates are used as the starting point. Comparative 
protein modeling can be split into two groups: homology modeling and fold recognition. 
Homology modeling is based on the hypothesis that proteins sharing sequence similarity 
may also share structural similarity. The sequences of templates are the homologies of the 
protein sequence to be predicted (the target). Homology modeling can generate high-
quality models if sequence homologies exist in the template database. However, homology 
modeling is not suitable for proteins for which homological templates are not available. 
Also, protein structures are more conserved in evolution than protein sequences [97], 
therefore proteins with similar structures may not be homologous in sequences [98].  
Fold recognition, also known as threading, is designed to model protein 3D structures 
based on structural similarity. Threading is a technique to match the query protein sequence 
directly on to the known 3D structures [96, 99], which aims to recognize fold similarity 
even when there is no evolutional relationship between the target and the structure 
templates. The threading method differs from the homology modeling as threading is used 
for proteins which do not have solved structures of their homologous proteins, whereas 
homology modeling is used for proteins which have their homologous protein structures 
solved. The protein threading method consists of several general steps: 1) the construction 
of a structure template database, or the selection of structure templates from a protein 




measure the similarity or fitness between the target and the templates; 3) threading 
alignment to align the target sequence with each of the structure templates by optimizing 
the designed scoring function; and 4) the threading prediction. This last step determines 
the most probable structures from the structure pools generated in the previous steps. 
Finally, the structure models are constructed by placing the backbone atoms of the target 
sequence at their aligned backbone positions in the selected structural templates. 
Some preconditions are necessary for the success of fold recognition, such as the 
availability of good structural templates in the template database and the ability to 
recognize good templates. In regard to the former precondition, structure databases, such 
as RCSB PDB, are good repositories for structure templates. In regards to the latter, to date, 
some threading methods, such as threading assembly refinement (TASSER), can 
successfully build high-quality full-length protein models with an average root-mean-
square-deviation (RMSD) of 2.25 Å. I-TASSER is a protein structure prediction package 
which implements the TASSER threading method. It is ranked the first of template-based 
prediction methods in several Critical Assessment of Protein Structure Prediction (CASP) 
competitions [96] and widely recognized as one of the best methods for protein structure 
prediction.  
Although template-based modeling is an essential approach for protein structure 
prediction [100], there are proteins with no sufficient sequence homologies and structural 
analogies. In this situation, the current template-based modeling lack the ability to 
successfully find appropriate templates. Here, the structure prediction has to be done from 
the first principle, or ab initio. The ab initio methods try to predict protein 3D structures 




laws, molecules adopt conformations where their energy achieves the global minima on 
the potential energy surface. It is difficult to search the global minima of the complex 
potential energy at the all-atom level for large proteins with more than 100 amino acids. 
The conformation sampling needs substantial computational resources, especially for 
proteins with large sizes. This limits the ab initio methods to prediction of proteins with 
relatively small sizes. S. Ołdziej et al. designed a hierarchical physics-based protein 
structure prediction methods which searches the global minima in a united atom force field. 
When compared the predicted structures of a 102-residue target to the native structure, the 
RMSD value is 7.4 Å [101].  
Currently, the boundary between template-based methods and ab initio methods is 
blurred. These two types of methods can be combined to improve prediction performance. 
For example, the Rosetta ab initio protein structure modeling application uses small 
structure segments, usually with the length of 3 or 9 amino acids, to generate initial 
structures [102]. I-TASSER uses the ab initio methods to do the modeling when structural 
templates are not available [96].  
With the improvement of computational capacity, 3D structure prediction algorithms 
can now predict protein structures at the atomic level, leading to practical applications to 
understand pathogenesis at this level of resolution. For example, I-TASSER [96, 93] has 
been successfully applied in structural and functional modeling of proteins related to 
studies of aging, cancer, diabetes, and other diseases [94, 103, 104]. These complementary 
computational studies bring new insights into pathogenesis and potential treatments for 
these diseases. The advances in protein structure prediction are systematically reviewed at 




competition to test state-of-the-art protein structure prediction methods.  
 
Molecular Dynamics Simulation 
 
Molecular dynamics (MD) simulations are computer simulations that intend to model 
the physical movement of atoms and molecules. During the simulation, the atoms and 
molecules interact in the simulation system for a period of time, thus allowing the analysis 
of the atom movement and bonds between the atoms. MD simulation is an excellent tool 
for the study of the thermodynamic and kinetic properties of biomolecules and many 
publications report both their success and limitations [106, 107].  
In MD simulations, mathematical functions are used to describe the potential energy of 
the system particles, the forms and parameters of which are called the force field. “All-
atom” force fields provide parameters for every type of atom in a system. 3D structure 
prediction finds the static structures with the lowest energy, whereas MD simulations can 
reveal the process of the folding and motion of the molecules.  
Using MD simulations, several researches have studied the stability, folding, and 
aggregation properties of polyQ tracts [83, 108-110]. A brief summary of the simulation 
work on polyQ is listed in the “Introduction” section in Chapter 5 of this dissertation. In 
this dissertation, MD simulations are applied to study secondary structure ensemble, water 
accessibility, and other structural propensities of polyQ segments to investigate the 
mechanisms of polyQ protein aggregation.  
  
Specific Aims of This Dissertation  
 
In this dissertation, state-of-the-art informatics and computational simulation 




of the pathogenesis mechanisms of polyQ diseases. The effects of polyQ enlargement on 
protein folding, conformational stability, and water accessibility of polyQ proteins are 
studied to explore the pathogenesis of polyQ diseases. Three specific aims are addressed 
in this dissertation: 
1) To compare and validate the predicted structures in polyQ disease relevant proteins 
(Chapter 2); 
2) To study the effect of the polyQ lengthening on protein folding, hydrogen bonding, 
and water accessibility of full-length polyQ proteins using protein structure prediction 
methods (Chapter 3 and Chapter 5); 
3) To study the effect of solvation on the folding stability and solvent-polyQ 
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The expansion of polyglutamine (polyQ) repeats in several unrelated proteins is 
associated with at least ten neurodegenerative diseases. The length of the polyQ regions 
plays an important role in the progression of the diseases. The number of glutamines (Q) 
is inversely related to the onset age of these polyglutamine diseases, and the expansion of 
polyQ repeats has been associated with protein misfolding. However, very little is known 
about the structural changes induced by the expansion of the repeats. Computational 
methods can provide an alternative to determine the structure of these polyQ proteins, but 
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In this paper, two popular protein structure prediction programs, I-TASSER and 
Rosetta, have been used to predict the structure of the N-terminal fragment of a protein 
associated with Huntington’s disease with 17 glutamines. Results show that both programs 





Both I-TASSER and Rosetta can be used for structure prediction of proteins with polyQ 
repeats. Knowledge of polyQ structure may significantly contribute to development of 




Knowledge of protein structure can be critical for devising therapeutic strategies for 
diseases in which protein dysfunction contributes to pathogenesis. For the polyglutamine 
(polyQ) diseases, pathogenic polyQ expansions typically cause gains of toxic functions 
associated with protein misfolding or aberrant interactions with RNAs or other proteins 
[1]. At least ten neurodegenerative disorders are caused by polyQ expansions, including 
Huntington’s disease (HD), dentatorubral and pallidoluysian atrophy (DRPLA), spinal and 
bulbar muscular atrophy (SBMA), and the polyQ spinocerebellar ataxias [2] (SCA1, 
SCA2, SCA3, SCA6, SCA7, SCA8, and SCA17) [3-5]. The proteins involved in these 
diseases have no significant sequence, compositional or structural homologies [6, 7] and 
numerous studies and observations have established that the length of the polyglutamine 




Analysis from patients’ data reveals that the expansion of polyglutamine repeats beyond 
certain pathological threshold causes the disease phenotype (Table 1.1) [9-12]. Also the 
number of the glutamines in the polyglutamine region is inversely correlated with age of 
onset [9, 13-17]. For instance for SCA2, people with 32 or 33 repeats tend to first 
experience symptoms of SCA2 in late adulthood, while people with more than 45 repeats 
usually have symptoms by their teens [2].  
One possible mechanism for these diseases pathology is the assembly of unfolded 
protein monomers into β-sheet amyloid fibers [18]. Both in vivo and in vitro studies have 
shown that the polyQ expansion may lead to protein misfolding [19] and may cause a 
structure transition to form parallel β-helix and β-sheet folds [20]. Protein misfolding and 
aggregation has been shown to depend on the polyQ length and the concentration of the 
protein [21-23]. As shown in [24] the polyQ tract will form β-sheet structures when the 
number of the Qs increases resulting in an increase of the chance of aggregation. Therefore 
the understanding of the effect of the lengthening of the polyQ repeat segment on protein 
folding can provide new insights and perhaps therapies for these diseases. 
Although the association of the lengthening of the polyQ repeats with the related 
polyglutamine diseases has been known for almost 20 years [25, 26], high-resolution 
structural analysis of these proteins in their native context has eluded researchers [27] and 
only very limited experimental information exists. Kim has crystallized multiple structures 
of the N-terminal segment of huntingtin protein with 17 and 36 glutamines repeats [28, 
29], finding that the polyQ regions exhibit conformational flexibility with α-helix, random 
coil, and extended loops [28, 29]. These structures are the only crystal structures of polyQ 




valuable insights into this problem [23, 30, 31], but to our knowledge no comprehensive 
studies have been reported comparing the 3D structures predicted for these segments with 
the limited experimental data available.  
The accuracy of the structures obtained using 3D structure prediction programs is 
improving rapidly, and some of the commonly available programs have shown excellent 
performance in the CASP competition [32]. However, all the 3D structure prediction 
programs are trained with a variety of proteins and their performance is usually evaluated 
on a general dataset [33]. There is no literature evidence reporting the performance of these 
programs on proteins containing polyQ tracts. So it is necessary for us to evaluate the 
performance of these programs before we use them to predict the structure of 
polyglutamine disease proteins at large scale. 
In this paper we present our results of the evaluation of the prediction performance of 
two efficient and popular 3D structure prediction programs, I-TASSER and Rosetta, on the 






We searched the RCSB PDB database [34] for structures with more than 10 consecutive 
glutamines in their sequences on November 2012. A total of 11 structures were retrieved, 
including 7 of the first exon of the huntingtin protein with 17 glutamines (HTT17Q-EX1) 
[28] and 4 of the first exon of huntingtin protein with 36 glutamines (HTT36Q-EX1) [29]. 
Figure 2.1(a) shows the sequence construction for the X-Ray diffraction experiment on 
HTT17Q-EX1 which was expressed and crystallized as a maltose-binding (MDP) fusion 





















Figure 2.1 The sequence construction of HTT17Q-EX1. (a) sequence structure of the PDB 







but the resolution of the HTT36Q-EX1 is of such poor quality that only HTT17Q-EX1 
structures were used in this study.  
PDB identification numbers of the 7 HTT17Q-EX1 crystal structures used here are 
3IO4 [PDB: 3IO4], 3IO6 [PDB: 3IO6], 3IOT [PDB: 3IOT], 3IOU [PDB: 3IOU], 3IOR 
[PDB: 3IOR], 3IOV [PDB: 3IOV] and 3IOW [PDB: 3IOW]. Each crystal includes a trimer 
of MDP-HTT17Q-EX1, so a total of 21 structures of HTT17Q-EX1 were considered. 
Figure 2.1 (b) shows the sequence of the HTT17Q-EX1 used as the input of the 3D 
structure prediction.   
 
Protein 3D Structure Prediction  
 
Two protein structure prediction programs were used in this study, I-TASSER and 
Rosetta. Both I-TASSER and Rosetta have been used by thousands users and they are 
among the few programs which can handle large proteins with more than 1000 residues 
[35, 36].   
I-TASSER is the 3D structure prediction program based on multiple-threading 
alignments and iterative template fragment assembly simulations [37]. I-TASSER is a fully 
automated method and was used without further modifications, but we have verified that 
none of the templates corresponding to the structures 3IO4 [PDB: 3IO4], 3IO6 [PDB: 
3IO6], 3IOT [PDB: 3IOT], 3IOU [PDB: 3IOU], 3IOR [PDB: 3IOR], 3IOV [PDB: 3IOV] 
and 3IOW [PDB: 3IOW] was included in the knowledge data used in the version of I-
TASSER used here. Rosetta is a flexible software suite for macromolecular modeling, 
which includes tools for structure prediction and design [38]. Rosetta ab initio module was 
used in this study. For Rosetta, the quota protocol fragment picking was used to generate 




by PsiPred [39], Jufo9D Server [40] and SAM-T08 [41] as the quota pools. The weight 
given to the each quota pool was assigned following reference [42] and 200 fragments were 
picked from the total of 700 candidates available from both 3-mers and 9-mers fragments. 
The default parameters were used for Rosetta ab initio modelling with the number of output 
structures set as 5000, the default parameters also were used for Rosetta cluster module.  
We installed I-TASSER Version 2.1 and Rosetta Version 3.4 in a cluster at the Center 
for High Performance Computing (CHPC) of University of Utah, where all computations 
were performed. As a fully automated program, the number of decoys to screen and the 
number of simulation jobs in I-TASSER are fixed, whereas Rosetta is much more flexible 
and users can define the output number of structures and the number of parallel simulation 
jobs, making it much more adaptable to the hardware architecture used. So it is difficult to 
compare the computational cost of the two programs. However, for the modelling tasks 
with the parameters used in our simulation, the total CPU time for I-TASSER to finish one 
HTT17Q-EX1 (60 amino acid residues) prediction was, in average, 24.58 hours using one 
core in a 2.4 GHz dual-core Opteron processor, whereas the average total CPU time for 
Rosetta to finish one HTT17Q-EX1 prediction with 5000 prediction structures was about 
50.91 hours in the same computing environment.  
  
3D Structure Alignment  
 
To assess 3D structure similarity, TM-align was used for structure comparison and 
alignment [43]. The TM-score calculated by TM-align, which lies in (0,1] interval, is 
considered a good measure of the similarity of two structures [44]. A TM-score of less than 
0.17 indicates a random alignment, whereas TM-score greater than 0.5 indicates that the 






Besides the TM-score, exact structure overlap (ESO) and exact structure overlap of 
polyQs (ESOP) were also used to measure the similarity of two structures. The words 
‘exact’ here means the aligned residues are within certain threshold, 5Å in this study, and 
that they are the same residue in the HTT17Q-EX1 sequence. For example, if a serine 
(SER) in the 16th position of the predicted structure of HTT17Q-EX1is aligned, within the 
distance threshold, with the serine (SER) in the 16th position of PDB experimental 
structure, the 16SER-16SER is an exact match. ESO and ESOP is derived from the 
Structure Overlap (SO) which is a standardized score to compare the structure alignments 
and measure the local similarity of two structures [45]. The SO score is calculated as:  
 
                                                      𝑆𝑂 = 100 ×
𝐿(𝐴)
𝑚𝑖𝑛(𝐿𝑚,𝐿𝑒)
                                                          (2.1) 
 
 
where L(A) is the structure alignment length; the Lm and Le are the length of the predicted 
model and the experimental structure, respectively.   
We have modified Equation (1) to meet the aim of more strict structure comparison, 
and get the ESO score:    
 
                                                     𝐸𝑆𝑂 = 100 ×
𝐿(𝐸𝐴)
𝑚𝑖𝑛(𝐿𝑚,𝐿𝑒)
                                             (2.2) 
 
 
where L(EA) is the length of exact match; Lm and Le is the length of predicted model and 
the length of the PDB experimental structure respectively. 
The structure of polyQ region may play a more important role than other positions. In 
this study, the ESOP score is calculated to evaluate the structure similarity of the polyQ 




                                                  𝐸𝑆𝑂𝑃 = 100 ×
𝐿(𝐸𝐴𝑄)
𝑚𝑖𝑛(𝐿𝑄𝑚,𝐿𝑄𝑒)
                                            (2.3) 
 
 
where L(EAQ) is the length of the exact match of Qs; LQm and LQe are the length of polyQ 
in predicted model and PDB experimental structure respectively. 
 
Secondary Structure Calculation  
 
The secondary structure of the predicted models and the PDB experimental structures 
were calculated using the DSSP algorithm, which is an algorithm to standardize secondary 
structure assignment [46]. Secondary structures assigned by DSSP are 8 conformational 
states, including α-helix, β-bridge, strand, 3-helix, 5-helix, turn, bend, and random coil. 
The results of DSSP are the secondary structures represented by one letter for each 
position. In order to get a better view of the results, “WebLogo 3” [47] was used to plot the 
secondary structure logo at each position. The overall height of the stack indicates the 
secondary structure conservation at that position, and the height of the symbols within the 
stack indicates the relative frequency of each secondary structure type at that position. 
 
3D Structure Visualization 
 
The 3D structure and the 3D structure superposition were visualized in the UCSF 




To depict the data distribution of the parameters calculated here, the (mean value ± 
standard deviation) is listed for data with normal distribution, whereas for data that do not 
follow the normal distribution, the 25% quantile and 75% quantile values are listed.  




ranked test was performed on other data sets to assess significance. The significant level 
was set at 0.05. All the statistic work was done in the R environment which is a free 






As evidence shows that the polyQ region can adopt different structures [28, 29] in the 
proteins of interest for polyQ diseases, it is not appropriate to seek the ‘best structure’ of 
this region, but it is more appropriate to look for ensembles of structures (generated by 
multiple independent runs) which can show overall trends and represent the variety of 
structures observed by experimental methods. 
Following this reasoning, both Rosetta and I-TASSER were run 10 times using 
different random seeds for each run of 3D structure prediction of the HTT17Q-EX1 
sequence shown in Figure 2.1(b). For each run we kept the five best models, so a total of 
50 I-TASSER models and 50 Rosetta models were retained for analysis.  
Each structure prediction program will return some parameters to estimate the accuracy 
of the models. For I-TASSER, the C-score, which lies in the (-5,2) range, is calculated for 
each model [35]. The C-scores of the best 50 I-TASSER models, listed in Table 2.1, range 
from -2.62 to -4.72.  
The clustering algorithm from Rosetta was used to identify the most frequently sampled 
conformations. For each run we selected the five structures with the lowest energy from 
the structures encountered in the five different clusters in which the number of structures 
was greater than 10 on each. The energies of the total 50 Rosetta structures, listed in Table 










Table 2.1 C-scores for the best I-TASSER models 
 
 
Model # 1 # 2 # 3 # 4 # 5 
Run 1 -2.91 -3.69 -3.33 -3.62 -4.72 
Run 2 -2.84 -3.71 -3.31 -3.5 -4.42 
Run 3 -2.81 -3.76 -3.48 -3.89 -3.74 
Run 4 -2.62 -3.69 -3.32 -3.76 -3.49 
Run 5 -3.02 -3.21 -3.91 -4.11 -3.42 
Run 6 -2.67 -3.76 -3.48 -3.62 -4.37 
Run 7 -2.77 -3.42 -3.96 -3.3 -3.51 
Run 8 -3.09 -3.45 -4.09 -4.22 -4.27 
Run 9 -2.73 -3.61 -3.38 -3.76 -4.42 





Table 2.2 Energy for the best Rosetta models 
 
 
Model # 1 # 2 # 3 # 4 # 5 
Run 1 16.061 16.349 18.609 19.656 19.956 
Run 2 17.881 18.309 18.373 18.386 19.215 
Run 3 16.943 17.598 17.639 18.306 19.436 
Run 4 18.414 18.662 18.691 18.812 19.076 
Run 5 16.74 18.004 18.192 18.3 19.015 
Run 6 18.353 18.388 18.572 18.766 18.96 
Run 7 17.435 18.897 19.571 19.603 19.617 
Run 8 18.128 19.111 19.521 19.643 19.707 
Run 9 17.317 17.586 17.655 17.916 18.69 







Secondary Structure  
 
For better visualization, WebLogo [47] was used to display secondary structure 
patterns. The WebLogo of the secondary structures of the experimental PDB structures and 
the best I-TASSER and Rosetta models are shown in Figure 2.2. For easy description, we 
divided the sequence into three regions: the 17-residue head region including residues 1 to 
17; the polyQ region including residues 18 to 34 and C-terminal region including residues 
35 to 60. As discussed in the original publication for the 21 PDB structures most crystals 
show α-helix in the head region, which is always well resolved, with only a few structures 
showing turns at the beginning and end of the head region. Both the I-TASSER and Rosetta 
best models reproduce the observed trends showing a majority of helix structures in the 
head region, but the I-TASSER structures show better agreement with the experimental 
findings showing a preference for α-helix, while the Rosetta structures show a mix of α-
helix and 3-helix. The secondary structure, for the resolved structures, in the polyQ region 
is more diverse showing a number of structures with α-helix, random coils, and turns. The 
Pro-enriched C-terminal region is dominated, at least for the resolved structures in this 
region, by coil structures. Unfortunately, as depicted in Figure 2.2(a), the number of well 
resolved structures rapidly decreases beyond the head region making comparison with the 
experiments less reliable. None-the-less the overall experimental trends are reproduced by 
both I-TASSER and Rosetta, but it appears that the I-TASSER structures show more loops 
than the experimental data.  
Overall I-TASSER appears to be superior reproducing quite well the stable α-helix 
structure of the N-terminal regions and showing increased diversity of structures in the 












Figure 2.2 Secondary structure WebLogo. (a) PDB structures; (b) I-TASSER models; (c) 
Rosetta models. In (a) M represents the number of structures with missing values due to 
lack of resolution in the experimental data. The codes for secondary structure are as 
follows: H: α-helix; B: β-bridge; E: Strand; G: Helix-3; I: Helix-5; T: Turn; S: Bend; C: 




Reproducibility of I-TASSER and Rosetta Results  
 
In order to test the sensitivity of I-TASSER and Rosetta with the selection of the seeds 
used in the calculations, we have calculated the structure similarity using the TM-score 
between models obtained using the same prediction program. A total of 1225 TM-scores 
were generated comparing pairwise the best 50 I-TASSER and 50 Rosetta models, 
respectively. 
TM-scores between any two models from I-TASSER range from 0.2781 to 0.7163, 
with an average of 0.4086 and a standard deviation 0.0692. Whereas the TM-scores 
between any two Rosetta models range from 0.2865 to 0.8236, with an average of 0.4979 
and a standard deviation 0.0892. The difference between TM-scores of I-TASSER and 
Rosetta is statistically significant (t-test, p<0.001, Figure 2.3). The number of TM-scores 
greater than 0.5 is two times greater for Rosetta/Rosetta pairs than for I-TASSER/I-
TASSER pairs, i.e., 561 pairs in Rosetta and 126 pairs in I-TASSER have scores larger 
than 0.5.  
When comparing only the best models of each run, the TM-scores range from 0.4539 
to 0.6813 for I-TASSER (Table 2.3) and from 0.2872 to 0.6879 for Rosetta (Table 2.4). 
Therefore the best models of each run from I-TASSER are more similar among themselves 
than those from Rosetta, i.e., 33 pairs of the 45 structure pairs have TM-scores greater than 
0.5 for I-TASSER, whereas for Rosetta, only 18 pairs of best models have TM-scores 
greater than 0.5. 
The sensitivity to the selected random seeds was also evaluated at the run level. 
TM-scores were calculated for the structures of any 5 models in one run compared with 





























Table 2.3 TM-scores between the best models from I-TASSER 
 
 
run # 2 # 3 # 4 # 5 # 6 # 7 # 8 # 9 # 10 
# 1 0.48 0.48 0.63 0.48 0.54 0.57 0.49 0.51 0.46 
# 2 
 
0.56 0.54 0.55 0.48 0.54 0.45 0.58 0.46 
# 3 
  
0.54 0.63 0.53 0.51 0.54 0.56 0.51 
# 4 
   
0.50 0.52 0.66 0.49 0.56 0.49 
# 5 
    
0.60 0.51 0.58 0.59 0.54 
# 6 
     
0.51 0.68 0.54 0.49 
# 7 
      
0.50 0.57 0.45 
# 8 
       
0.50 0.52 
# 9 





Table 2.4 TM-scores between the best models from Rosetta 
 
 
run # 2 # 3 # 4 # 5 # 6 # 7 # 8 # 9 # 10 
# 1 0.30 0.43 0.37 0.42 0.42 0.53 0.40 0.38 0.43 
# 2 
 
0.30 0.34 0.31 0.39 0.28 0.34 0.32 0.38 
# 3 
  
0.52 0.53 0.53 0.65 0.47 0.57 0.50 
# 4 
   
0.48 0.53 0.47 0.68 0.49 0.43 
# 5 
    
0.63 0.52 0.48 0.58 0.61 
# 6 
     
0.52 0.47 0.64 0.59 
# 7 
      
0.41 0.56 0.55 
# 8 
       
0.46 0.42 
# 9 








any two experiments is shown in Table 2.5 for I-TASSER and Table 2.6 for Rosetta. For 
I-TASSER, the number of pairs with TM-score greater than 0.5 ranges from 0 to 6. There 
are 6 pairs with TM-scores greater than 0.5 between Run 4 and Run 7, however, no pairs 
with TM-scores greater than 0.5 between Run 1 and Run 8. For Rosetta, the number of 
pairs with TM-score greater than 0.5 at run level ranges from 5 to 20. 20 of 25 pairs are 
with TM-scores greater than 0.5 between Run 3 and Run 7, which is the best. The smallest 
number of pairs for Rosetta is 5, which shows in 3 pairs, Run 1 and Run 6, Run 6 and Run 
8, Run 5 and Run 8.  
These results show that our ensemble approach to predict the structure of proteins 
associated with polyQ diseases appears to be appropriate. Using multiple seeds it is 
possible to obtain an ensemble of structures that show reasonable diversity, but still retain 
the main features. We believe that this approach is quite promising because it can 
incorporate in future analysis the diverse structure of which appears to be an emerging 
observation from the limited experimental data on these proteins. 
 
Validity Evaluation of I-TASSER and Rosetta 
 
As depicted in Figure 2.2(a) not all of the 21 PDB structures have been resolved in the 
polyQ region, which is our main interest. For instance, the longest well resolved polyQ 
region is the B chain of the 3IOW [PDB: 3IOW] structure in which all the 17 Qs structures 
are resolved, whereas for the A chain of the 3IOT [PDB: 3IOT] structure only one Q has 
been resolved. Also, there are numerous gaps in several structures as some of the residues 
are not resolved. Taking this into account and in order to make an accurate comparison 
with the experimental ones in the region of interest, only PDB structures in which at least 










Table 2.5 Number of pairs with TM-score greater than 0.5  
                       between any two runs of I-TASSER 
 
 
run # 2 # 3 # 4 # 5 # 6 # 7 # 8 # 9 # 10 
# 1 2 3 3 1 3 3 0 5 1 
# 2  2 2 2 2 3 2 2 1 
# 3   3 3 2 3 2 1 4 
# 4    3 2 6 3 5 1 
# 5     3 5 3 2 4 
# 6      4 1 5 2 
# 7       4 5 2 
# 8        3 2 




Table 2.6 Number of pairs with TM-score greater than 0.5  
                             between any two runs of Rosetta 
 
 
run # 1 # 2 # 3 # 4 # 5 # 6 # 7 # 8 # 9 # 10 
# 1 4 6 10 11 8 5 11 12 8 9 
# 2 
 
2 11 8 7 6 13 11 11 10 
# 3 
  
6 15 9 13 20 16 18 16 
# 4 
   
3 9 7 14 13 16 14 
# 5 
    
4 8 15 5 16 15 
# 6 
     
1 8 5 13 9 
# 7 
      
5 15 16 14 
# 8 
       
8 7 13 
# 9 
        
9 17 
#10 








resolved structures were used for the evaluation of the results produced with I-TASSER 
and Rosetta. There are ten PDB structures that meet this criteria: the B chain of 3IO4 [PDB: 
3IO4] (3io4_b), the C chain of 3IO4 [PDB: 3IO4] (3io4_c), the B chain of 3IO6 [PDB: 
3IO6] (3io6_b), the C chain of 3IO6 [PDB: 3IO6] (3io6_c), the C chain of 3IOR [PDB: 
3IOR] (3ior_c), the B chain of 3IOT [PDB: 3IOT] (3iot_b), the C chain of 3IOU [PDB: 
3IOU] (3iou_c), the B chain of 3IOV [PDB: 3IOV] (3iov_b), the C chain of 3IOV [PDB: 
3IOV] (3iov_c), and the B chain of 3IOW [PDB: 3IOW] (3iow_b). The number of 
consecutive Qs in each structure is shown in Table 2.7.    
The best 50 I-TASSER and 50 Rosetta models were compared with these 10 PDB 
structures using the TM-align program. TM-scores, root-mean-square deviation (RMSD), 
aligned number of residues, sequence identity and the structure superposition were 
obtained from TM-align [43]; the number of exact matches and the number of exact 
matched Qs were extracted from the structure alignment and finally the exact structure 
overlap (ESO) and exact structure overlap of Qs (ESOP) were calculated using Equation 
(2.2) and Equation (2.3) given in the methods section. The values of each similarity 
parameter considered here are shown in Table 2.8 along with the p-values assessing the 
significance of the difference between the I-TASSER and Rosetta results. 
The average TM-score of I-TASSER/PDB superposition pairs is 0.50 and the average 
TM-score of Rosetta/PDB pairs is 0.45, reflecting the fact that 253, of the 500, 
I-TASSER/PDB pairs have TM-scores greater than 0.5 while only 87 pairs of the 
Rosetta/PDB pairs have TM-scores greater than 0.5. The average RMSD of 
I-TASSER/PDB pairs (1.53 Å) is also smaller than that of Rosetta/PDB pairs (1.74 Å). 






Table 2.7 Numbers of Qs in  
                                               the PDB structures 
 
 














Table 2.8 Distribution of structure superposition parameters between  
              predicted models and PDB structures  
 
 
 I-TASSER Rosetta p-value 
TM-score 0.50±0.06 0.45±0.06 <0.0001 
RMSD (Å) 1.53±0.34 1.74±0.34 <0.0001 
Aligned number 24.05±2.14 25.56±2.41 <0.0001 
Sequence Identity a (0.30,0.71) (0.38,0.52) <0.0001 
Exact Match (<5.0 Å) a (0,16) (0,0) <0.0001 
Exact Qs Match(<5.0 Å) a (0,1) (0,0) <0.0001 
Total Qs Match(<5.0 Å) a (5,8) (8,11) <0.0001 
Exact Match (other) a (0,0) (0,0) <0.0001 
Exact Qs Match(other) a (0,0) (0,0) <0.0001 
Total Qs Match(other) a (0,1) (0,1) <0.0001 
Exact Match (all) a (6,25) (0,0) <0.0001 
Exact Qs Match (all) a (0,1) (0,0) <0.0001 
Total Qs Match (all) a (6,8) (9,12) <0.0001 
ESOP a (0,9.09) (0,0) <0.0001 
ESO a  (0, 53.13) (0,0) <0.0001 
a The values between brackets represent the value of the property for the best structure 






than Rosetta in this test. 
The structure overlap scores, ESOP and ESO, for I-TASSER models are also better 
than those for Rosetta models. For instance more than 75% of the Rosetta models have no 
exact match in the polyQ region nor for the entire sequence, whereas the 75% quantile of 
the ESO and ESOP scores for I-TASSER are 53.13 and 9.09, respectively. The statistical 
tests have shown that these differences are significant (Table 2.8). 
Fifty of the I-TASSER/PDB structure superpositions have ESOP values greater than or 
equal to 50, which means that 50 pairs have more than 50% of Qs in the polyQ region with 
exact match. These 50 pairs include 9 of the 10 PDB structures, so 9 of the 10 structures 
have corresponding I-TASSER models with very good matches in the polyQ regions. In 
contrast only 5 of these 10 structures have corresponding Rosetta/PDB structure 
superposition matches when the same criteria are used. 
The best matches between the predicted structures by I-TASSER and Rosetta, 
respectively, and one of the PDB structures considered here are depicted in Figure 2.4. The 
I-TASSER structure best match is with the B chain of 3IO6 [PDB: 3IO6]; the match has a 
TM-score of 0.56 and the ESOP score of 100. The best two matches for Rosetta structures 
show matches with the C chain of 3IOU [PDB: 3IOU] and the B chain of 3IOW [PDB: 




This study evaluated two software tools for predicting, from amino acid sequences, the 
3D structures of the polyQ regions of proteins related to polyglutamine diseases. 
Pathogenic neurodegenerative polyQ proteins were used as a model, for relevance to 










Figure 2.4 Structure superposition of predicted models and PDB structures. Structure 
superposition of predicted models and PDB structures with TM-score>0.5 and ESOP=100. 
(a) I-TASSER third model in the tenth run with 3io6_b; (b) Rosetta forth model in the first 
run with 3iou_c; (c) Rosetta third model in the fifth run with 3iow_b. Tan: PDB structure; 




structures. Two highly recognized and efficient 3D structure prediction programs, I-
TASSER and Rosetta, were evaluated to assess their performance for structure prediction 
using segments of the huntingtin protein harboring polyQ repeats. Both I-TASSER and 
Rosetta produced good results. 
When tested for structure stability under changes of the initial random seed, Rosetta 
shows less variability than I-TASSER. This means that if we run Rosetta and I-TASSER 
several times respectively, it is possible that we will get less variance in the results from 
Rosetta than from I-TASSER. Nonetheless, both programs produce a reasonable ensemble 
of structures with sufficient diversity and without extreme deviations. Several studies have 
illustrated that the polyQ repeat regions of these proteins are highly disordered with 
structure flexibility [31], but this has not been quantified experimentally. Therefore it is 
challenging to discriminate among these two approaches using these criteria. In 
consequence we must conclude that both I-TASSER and Rosetta are suitable for the task 
on predicting ensemble structures of protein containing polyQ segments.  
The accuracy of the prediction program is a very important factor that we evaluated 
here. In this study, the structure similarity between the predicted models and the PDB 
experiment structures available was used to evaluate the validity of the prediction 
programs. The root-mean-square deviation (RMSD) score is the most often-used parameter 
to calculate the structure similarity, but a drawback of its use is that a relatively small local 
variation can result in a high RMSD [44]. TM-score weights the close atom pairs stronger 
than the distant matches, and it is more sensitive to the topology fold than the RMSD [44]. 
Besides the global similarity measured by TM-score, more restricted scores on the exact 




from the structure overlap (SO) score [45], was introduced and instead of calculating the 
number of aligned pairs it counts the exact match pairs, which not only counts aligned 
residues but also residues that lie in the same positions in both the sequences of predicted 
model and PDB structure. The exact structure overlap of polyQ repeat (ESOP) is the special 
version of ESO, which is used to measure the prediction accuracy in the polyQ region. 
Considering the TM-score, ESO and ESOP together gives a more comprehensive view of 
similarity between the predicted model and the PDB experimental structures from both a 
global and a local aspect. The ESO score and ESOP score can be used for similarity 
comparison tasks, especially if there are regions which play more critical roles than others. 
Rosetta models have a larger number of aligned residues on average than I-TASSER, 
but the average RMSD values and TM-scores are much higher (lower) than that of 
I-TASSER. So when the Rosetta models are aligned with the PDB structures, the distance 
between the models and the experimental structures is large, which is not a good sign for 
good structural matches. On the contrary, I-TASSER models aligned better with PDB 
structures not only with better RMSD and TM-scores, but also better ESO and ESOP 
scores. This can also be seen from the secondary structures patterns. When considering 
specific structure pairs, both I-TASSER and Rosetta have predicted models which can 
match the PDB structures with good global (TM>0.5) and local (ESO>=50 and 
ESOP>=50) structures. So both Rosetta and I-TASSER have the ability to get the native 
models, but for the overall performance, I-TASSER appears to be better than Rosetta.   
As several models are returned by the structure prediction programs, it is important to 
have criteria to select the best models. However, the model with the lowest energy in the 




instance for Rosetta, the two predicted models with TM-score greater than 0.5 and ESOP 
of 100 (Figure 2.4(b) and 4(c)) are not the models with the lowest energy in that Rosetta 
run. This is true also for the I-TASSER model with TM-score greater than 0.5 and ESOP 
of 100 (Figure 2.4(a)). In fact, of the 29 good models which have TM-score greater than 




Both I-TASSER and Rosetta can be used for in silico studies of the structures of 
proteins with polyQ repeats related to neurodegenerative diseases. However, I-TASSER 
shows better performance than Rosetta when considering the overall agreement between 
results produced using these two prediction models with the limited experimental results 
available for comparison.  
Both I-TASSER and Rosetta are computationally efficient as both applications can be 
easily parallelized by executing numerous jobs each with a unique random seed.  
In our future studies we will attempt to predict the change of the structure as function 
of the number of Qs in the polyQ repeat segment for all the proteins involved in polyQ 
neurological diseases. Ideally we could use both these two programs to predict structures 
of the polyQ disease related proteins. This could provide a quasi “crowdsourcing” 
mechanism to cross check the results, but may prove computationally too expensive (see 
Methods). Therefore the results presented here suggest that studies should be, at least 
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Spinocerebellar ataxia type 2 (SCA2) and type 3 (SCA3) are two common 
autosomal-dominant inherited ataxia syndromes, both of which are related to the unstable 
expansion of tri-nucleotide CAG repeats in the coding region of the related ATXN2 and 
ATXN3 genes, respectively. The poly-glutamine (polyQ) tract encoded by the CAG 
repeats has long been recognized as an important factor in disease pathogenesis and 
progress. In this study, using the I-TASSER method for 3D structure prediction, we 
investigated the effect of polyQ tract enlargement on the structure and folding of ataxin-2 
and ataxin-3 proteins. Our results show good agreement with the known experimental 
structures of the Josephin and UIM domains providing credence to the simulation results 
presented here, which show that the enlargement of the polyQ region not only affects the 
local structure of these regions but also affects the structures of functional domains as well 
as the whole protein. The changes observed in the predicted models of the UIM domains 
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Protein misfolding and aggregation is a pathogenic feature shared among at least ten 
polyglutamine (polyQ) neurodegenerative diseases. While solvent-solution interaction is a 
key factor driving protein folding and aggregation, the solvation properties of expanded 
polyQ tracts are not well understood. By using GPU-enabled all-atom molecular dynamics 
simulations of polyQ monomers in an explicit solvent environment, this study shows that 
solvent-polyQ interactions decrease as the lengths of polyQ tracts increase. This study finds 
a predominance of long-distance interactions between residues far apart in polyQ 
sequences in longer polyQ segments, that leads to significant conformational differences. 
This study also indicates that large loops, comprised of parallel β-structures, appear in long 








distance intra-polyQ interactions. Finally, consistent with previous observations using 
coarse-grained simulations, this study demonstrates that there is a gain in the aggregation 
propensity with increased polyQ length, and that this gain is correlated with decreasing 
ability of solvent-polyQ interaction. These results suggest the modulation of solvent-polyQ 




The polyglutamine (polyQ) diseases are caused by unstable expansions of CAG repeats 
resulting in proteins with expanded polyQ tracts. The polyQ diseases include Huntington’s 
disease (HD), the spinocerebellar ataxias (SCAs 1, 2, 3, 6, 8, 7, 17), dentatorubral-
pallidoluysian atrophy (DRPLA), and spinal and bulbar muscular atrophy (SBMA) [1-6]. 
Pathogenesis in these diseases is associated with abnormal polyQ protein folding [7-9] and 
resultant neuronal inclusion body formation [10, 8, 11-14]. While polyQ protein folding, 
stability, and aggregation have been well described for the polyQ diseases [15, 16], the 
molecular mechanisms leading to protein misfolding and aggregation, at the atomic level, 
are not well understood. 
Computational simulations, using a variety of approaches, are used by several 
publications to study polyQ aggregation. In order to provide context to the relevance of the 
studies presented here, this section briefly discusses how computational simulations are 
applied in the study of structure and aggregation of polyQ. Laghaei and Mousseau [17] 
performed Replica-Exchange Molecular Dynamics (REMD) simulations of polyQ 
monomers and dimers with 30Q to 50Q repeats in length, with an implicit solvent force 
filed, and observed that polyQ dimers with more than 40 repeats adopt antiparallel β-sheets, 




simulation methods, explored the conformation ensemble of short monomeric polyQ tracts 
with 15 glutamines. They find that Q15 monomers can assume multiple configurations and 
that the formation of oligomers is stabilized by the β-turns and hydrogen bonds between 
the main chains. The same authors performed REMD [19] on short polyQ monomers and 
dimers with lengths ranging from 3Q to 15Q; their results demonstrate that polyQ dimers 
strongly favor the formation of antiparallel β-sheet structures. Chiang et al.[20] studied the 
aggregation of short polyQ segments with 15 residues using REMD with explicit solvent. 
Their results show that polyQ dimers mainly form helix and coil structures when they are 
far apart, but as the interpeptide distance decreases, an inter-peptide β-sheet is formed. 
Zhou et al. [21] studied the early stage of polyQ aggregation using initial β-helical 
structures of various shapes and sizes, which include left-handed circular, right-handed 
rectangular, and left- and right-handed triangular. Their results show that the stability of 
the β-helical structures increases as the number of rungs increases, and that the 3-rung left-
handed triangular and right-handed rectangular β-helical models are stable. Using the all-
atom REMD, Hayre et al. [22] find that the left-handed β-helical conformations are stable 
for polyQ tracts with 61 residues. To explore the stability of α-sheet configuration of 
polyQ, Babin et al. [23] performed Molecular Dynamics (MD) simulations in an explicit 
solvent environment on short polyQ dimers with 8 glutamines and find that the α-sheet 
configuration is a stable, metastable, or at least long-lived secondary structure. Miettinen 
et al.[24] assessed the stability of a 40Q polyQ segment with six different initial 
conformations, including steric zipper, β-nanotube, β-pseudohelix, β-sheetstack, β-sheet, 
and α-helix. Using atomistic MD simulations in explicit solvent, they find that β-hairpin-




to serve as a template to initiate polyQ fibrillation. The same group also studied the stability 
of polyQ dimers with the six initial conformations and finds that β-hairpin-containing 
conformers can form very stable dimers when their side chains are interdigitated, whereas 
dimers of α-helix, steric zipper, β-nanotube, and β-pseudohelix conformers are too short-
lived to initiate aggregation [25]. Using both 2D IR spectroscopy and MD simulation, 
Buchanan et al. determined that stacked β-hairpins are the dominant structure of polyQ 
fibrils [26]. Wang et al. [27] conducted solvent-free multiscale coarse-grained models on 
polyQ segments with lengths ranging from 8Q to 56Q, and find that the degree of 
aggregation increases with the length and concentration of polyQ chain. Deng et al. [28] 
studied the polyQ aggregation on Q32 using solvent-free multiscale coarse-gained MD 
simulations, and their results show that polyQ aggregation is sensitive to concentration and 
temperature changes. Lakhani et al. show that the β-rich region in the exon one of 
huntingtin protein misfolds with increasing polyQ lengths (Q23-Q47) [29]. Similarly, the 
work of Morida et al. finds the presence of a larger population of aggregation-forming 
structures in 40Q polyQ segments than in those below the pathogenesis threshold [30]. 
Stork et al. [31] studied the stability of several types of β-helix of polyQ, polyA, and polyS 
using MD simulations, and find that the water-filled channels inside the β-helix can 
destabilize the β-helix structures. This study demonstrates that protein-solvent interaction 
may compete efficiently with the intramolecular hydrogen bonds, affecting conformation 
stability and aggregation. However, few studies employ full explicit solvent MD 
simulations to evaluate solvent effects on polyQ aggregation as a function of the polyQ 
segment length.  




powerful means to further study solvent effects on the folding and aggregation properties 
of polyQ proteins, the high computational cost of all-atom and explicit solvent MD has 
been a major deterrence for this type of studies. The use of GPU acceleration hardware for 
MD simulations can efficiently speed up these calculations [32] and makes it possible to 
do atomic MD simulation with an explicit water environment in a reasonable time period 
[33]. Amber, one of the most popular MD programs, is able to use NVIDIA GPUs to 
massively accelerate MD for both implicit [34] and explicit solvent simulations [35, 36] 
with a dramatic performance improvement. Here we report the study of solvent effects on 
solution properties, folding, and aggregation propensity of simple polyQ sequences, which 
can be considered an initial and computable model for the study of solvent effects on the 
aggregation propensity of polyQ disease related proteins at the atomistic level [37]. Of note 
is that, even with the advances provided by the GPU technology, all-atom MD studies of 
full polyQ proteins in explicit solvent are still nonfeasible. Taking advantage of the GPU 
speedups, we are able to perform MD runs of these polyQ models with repeat lengths in 
both the normal and the pathological ranges, using explicit solvent and simulation lengths 
of 105 ns, within reasonable computational wall times.  
In this paper, we report results of 105 ns simulation of polyQ segments of different 
repeat lengths, in the range observed for polyQ diseases, using full atomistic MD 




The polyQ tract is the only common region observed in the otherwise very dissimilar 
polyQ proteins which are associated with polyglutamine diseases, and in all cases, the 




triggers these diseases is around 35 to 40 residues, except in SCA6 which has a shorter 
threshold of around 19 repeats [38-40]. Therefore, it is of interest to study the solvation 
behavior of polyQ segments shorter than 20 and longer than 40 repeats to find common 
features on how solvent interactions may affect the folding of such diverse set of proteins. 
We performed MD simulations for polyQ monomers with 18 repeats (Q18), 46 repeats 
(Q46) and 32 repeats (Q32). These correspond to lengths below the lowest known disease 
threshold, above the highest known normal threshold and the average repeat length of these 
two, respectively. The extended structure of polyQ was used as the starting structure of the 
MD simulations. In order to avoid complications due to charged termini [41], the polyQ 
sequences were capped with an acetyl group in the N-terminus and a N-methylamide group 
in the C-terminus, i.e., the structures considered here are [acetyl-(Gln)n-N-methylamide], 
where n = 18, 32, and 46 denotes the number of glutamines. xLEaP [42] was used to build 
the initial configurations, and the Amber force field, AMBER ff99SB force field[43], was 
used with a TIP3P water box to provide an explicit simulation of the solvent. A local 
minimization of the polyQ monomers was done in vacuum before the water box was added. 
The TIP3P water was included in a truncated octahedral box added to the polyQ monomer 
with a buffering distance of 9.0 Å between the edges of the box and the polyQ monomer. 
A second minimization was performed on the solvated system using a nonbonded cutoff 
distance of 9 Å to minimize the energy of the whole system. The whole system was then 
heated from 0 K to 310 K and equilibrated for 50 ps, followed by molecular dynamics 
simulations for 105 ns at the temperature of 310K and constant pressure of 1 atm. The 
temperature was maintained through the Berendsen thermostat with a coupling time of 0.1 




ps was used. The velocity was updated every 2 fs, and results were recorded every 1 ps.  
For each polyQ monomer, six independent runs were performed and the results 
presented here are the average for these runs. All the MD simulations were done using the 
Amber 14 molecular simulation package [44] which supports a GPU accelerated PMEMD 
module, that implements the Particle Mesh Ewald (PME) method for electrostatics [36]. 
All calculations were performed using the clusters at the Center for High Performance 
Computing (CHPC) at the University of Utah. Each computing node in the cluster has two 
Nvidia 2090 GPUs and 12 Intel Xeon (Westmere X5660) processors. After a preliminary 
study to optimize the efficiency of the GPU-accelerated computing nodes (results not 
shown), we performed one simulation per GPU to obtain the best throughput performance 
with the settings of our cluster.  
The Cpptraj utility in the Amber 14 tool box [44] was used for most of the analysis. 
The MD trajectories were re-imaged back to the primary box, and to speed up the analysis, 
only 1/100 of the frames were processed that is 100 ps per frame in the new trajectory. The 
secondary structure, hydrogen bond, solvent bridge, radius of gyration, and solvent surface 
area were calculated using Cpptraj for each simulation trajectory. The Rg value of the 
polyQ segments was calculated for each frame of the 105 ns and these values were used to 
calculate the exponent factor b in the Rg ~ Nb. The log transform was done on each data 
point, and a linear regression was fit to get the exponent factor b.  
For each polyQ length, the results of six independent simulations were averaged, such 
that all values reported here represent the average values over these six runs. Statistical 
analyses were performed using R [45], figures were plotted with ggplot2 package [46] and 






Overall GPU Performance 
 
The systems considered here, including both polyQ monomer and water solvent (Table 
4.1), are large enough to exhibit excellent scaling when using GPUs. The GPU version of 
the Amber PMEMD module on the GPU furnished nodes provides highly consistent 
speedups, with an average factor of 8.5 times speedup over the CPU times. 
 
Secondary Structure  
 
Our simulations show that polyQ monomers can adopt various secondary structures 
instead of fixed structures during the 105 ns simulations. This is consistent with previous 
results showing that polyQ monomers are disordered [37]. All monomers predominately 
adopt helical structures (Figure 4.1), but the types and proportions of each of the helical 
structures vary among monomers with different repeat lengths. Q18 monomers show the 
highest proportion of helical structures including 3-helix and α-helix, whereas Q32 
monomers adopt the lowest proportion of helical structures on average. It is apparent from 
Figure 4.1 that the number of β-structures, especially parallel ones, increases as the length 
of the polyQ segment increases. This is an important structural change as it has been 
established that parallel β-structures are a precursor for initiating aggregation [49].  
The stability of the β-structures, as a function of time, is also different for monomers 
of different lengths (Figures 4.2-4.4). The simulations show that the parallel β-structures 
in Q46 monomers are very stable and most of them can last for the entire simulations 
(Figure 4.4), whereas in Q18 and Q32 these structures are less stable, occurring only in 




















Table 4.1 Comparison of AMBER CPU and GPU performance for 
                   simulations of polyQ monomer in explicit solvent  
                   with different number of repeats. 
 
  




Q46 341,249 0.30±0.01 2.73±0.02 
Q32 134,359 0.86±0.00 7.49±0.04 










Figure 4.1 Secondary structure of polyQ fragments of different lengths. A Q18; B Q32; C 
Q46. Colours indicate different types of secondary structures. Blue: parallel β structure; 
Sky blue: antiparallel β structure; Dark green: 3-helix; Green: α-helix; Olive: pi-helix; Dark 
orange: turn; Red: bend; Black: loop. X-axis: residue index; Y-axis: percentage of frames 











Figure 4.2 Secondary structure of Q18 monomers at different time frames for each of the 
six independent MD runs performed. X-axis: frame index with each frame representing 
100 ps of simulation; Y-axis: residue index indicating the secondary structure as depicted 











Figure 4.3 Secondary structure of Q32 monomers at different time frames for each of the 
six independent MD runs performed.  X-axis: frame index with each frame representing 
100 ps of simulation; Y-axis: residue index indicating the secondary structure as depicted 











Figure 4.4 Secondary structure of Q46 monomers at different time frames for each of the 
six independent MD runs performed. X-axis: frame index with each frame representing 
100 ps of simulation; Y-axis: residue index indicating the secondary structure as depicted 






Hydrogen bonding plays a critical role in polyQ folding and stability [50], therefore 
changes in hydrogen bond patterns with polyQ expansion may be a signal of changes in 
folding and aggregation propensity. Of particular interest is the balance between intra-
polyQ and polyQ-solvent hydrogen bonds. In this study, we term the hydrogen bond as 
intra-polyQ if both donor and acceptor are from glutamine residues, and hydrogen bonds 
between glutamine residues and solvent water molecules are called solvent-polyQ 
hydrogen bonds. As the amide group in the sidechain of a glutamine can provide one 
hydrogen donor (hydrogen in NE2) and two hydrogen acceptors (NE2 and OE1), the intra-
polyQ sidechain hydrogen bonds can be both backbone-sidechain as well as sidechain-
sidechain hydrogen bonds. The hydrogen bonds are identified using the hbond command 
in Cpptraj program in the Amber 14 Toolbox. The distance cut-off is set at 3.5 Å, and the 
angle cut-off is set at 120°. Therefore, there can be more than one water molecule, 
surrounding one glutamine, which meet these criteria. So the number of hydrogen bonds 
reported in this study represents the dynamic count of the number of hydrogen bonds 
detected by Cpptraj over all six simulations.    
Intra-polyQ hydrogen bonds.  Using the procedure described above, the number of 
hydrogen bonds is counted for each individual frame in the 105 ns MD simulation for each 
MD run. The normalized count of hydrogen bonds per 100 Qs, which is the number of 
hydrogen bonds normalized by length of the polyQ segment multiplied by 100, is 
calculated as a measure of the relative ability of polyQ monomers to form hydrogen bonds.  
While longer polyQ monomers adopt more intra-polyQ hydrogen bonds than shorter 

















Figure 4.5 Intra-polyQ hydrogen bonding. A total number of intra-polyQ hydrogen bonds; 
B sidechain-sidechain hydrogen bonds. Ted: total count of hydrogen bonds; Blue: 




glutamines increases as the monomer length increases (Figure 4.5A, blue). There is a linear 
relationship between normalized intra-hydrogen bonds and monomer length (p<0.001, 
r=0.282). 
When considering intra-polyQ hydrogen bonds formed with the glutamine sidechains, 
the number of sidechain-sidechain hydrogen bonds increases with the number of 
glutamines in the polyQ tract (p<0.001, r=0.70) (Figure 4.5B, red). For polyQ monomers 
of the same length, the number of sidechain-sidechain hydrogen bonds is consistent among 
simulations, and independent of the secondary structure (Figure 4.6). When normalized by 
the number of glutamines in the polyQ tract, the normalized count of sidechain-sidechain 
hydrogen bonds per 100Qs also increases with polyQ length (p<0.001, r=0.30) (Figure 
4.5B, blue). The normalized count of hydrogen bonds per 100 Qs formed by glutamine 
sidechains, including both sidechain-sidechain and sidechain-backbone hydrogen bonds, 
are similar in 32 Q and 46Q polyQs, but are fewer in the 18Q polyQ (Figure 4.7).  
At the residue level, all polyQ tracts studied here show some common hydrogen bond 
patterns. The results of this study show that, in all of the repeat lengths studied here, the ith 
residue prefers forming hydrogen bonds with residues in the position of i+2, i+3 or i+4 
(Figure 4.8). We verified that both backbone-backbone and sidechain hydrogen bonds 
contribute to the patterns of i+2, i+3, and i+4, but that the backbone-backbone hydrogen 
bonds contribute more than sidechain ones. Some hydrogen-bonded residue pairs are ‘hot’ 
in all the polyQ segments studied here and this trend is independent of the lengths of the 
polyQ monomers. Residues 1 and 4 show hydrogen bond propensity in 4 out of the 6 MD 
simulation runs of 18Q, 32Q, and 46Q polyQ segments. In addition to these common 













Figure 4.6 Sidechain hydrogen bond. Red: sidechain-backbone hydrogen bond; Blue: 
sidechain-sidechain hydrogen bond. Shapes indicate different experiments. From left to 










Figure 4.7 Number of intra-polyQ hydrogen bond normalized by the length of polyQ 
monomer. X-axis: the length of polyQ monomer; Y-axis: the number of hydrogen bond. 

















Figure.4.8 Intra-polyQ hydrogen bond among different experiments. A, B, and C represent 
the total intra-polyQ hydrogen bond; D, E, and F represent the backbone-backbone 







ranged hydrogen bonds considered here are the ones formed by two glutamines with a 
sequence distance longer than at least half of the length of the polyQ monomer. The 
percentage of long-ranged hydrogen bonds is greater in the longer polyQ tracts than that 
shown in the shorter ones. For example, when considering hydrogen bonds with a time 
frequency greater than 50%, all of the hydrogen bonds in Q18 are short-ranged ones (Figure 
4.9), whereas 4.5% and 10.0% of the hydrogen bonds are long-ranged ones in Q32 and 
Q46, respectively. For Q32, the long-lived hydrogen bond can occur even between 
glutamines that are 15 residues apart in the polyQ sequence, and this distance can extend 
to 30 residues in 46Q polyQ monomers.  
Solvent-polyQ hydrogen bonding.  As expected, the number of solvent-polyQ 
hydrogen bonds, which are calculated using the criteria defined in the above section, 
increases as the length of polyQ monomers increases (Figure 4.10A). The slope of the 
increase is different among different types of hydrogen bonds, with sidechain solvent 
hydrogen bonds increasing the greatest (Figure 4.10A). However, when the total number 
of intra-polyQ hydrogen bond is normalized by the number of repeats in the polyQ 
segment, this normalized number of hydrogen bonds decreases as the polyQ length 
increases (Figure 4.10B), which is the reversed trend from what observed for the 
normalized number of intra-polyQ hydrogen bonds. When classified at the atomic level, 
the number of hydrogen bonds using each atom, shown in Figure 4.11, also increases with 
the length of polyQ (Figure 4.11A), with sidechain O-mediated hydrogen bonds increasing 
the greatest. However, when normalized by the polyQ segment length, the number of 
sidechain O-mediated hydrogen bonds decreases with the polyQ length, as did the 

















Figure 4.9 Distance distribution of observed hydrogen bonds with more than 50% 
frequency. The normalized distance is calculated as (|acceptor residue index-donor residue 



















Figure 4.10 Solvent hydrogen bond count. A total count; B count normalized by polyQ 



















Figure 4.11 Solvent hydrogen bond count at the atomic level. A total count; B count 





hydrogen bonds formed by other atoms do not change substantially, and are similar among 
polyQs with different lengths (Figure 4.11B).   
Intra-polyQ hydrogen bond vs. solvent-polyQ hydrogen bond.  For each simulation 
time frame, the potential number of intra-polyQ hydrogen bonds and the potential number 
of solvent-polyQ hydrogen bonds are calculated and the values are plotted in Figure 4.12. 
As expected, there is strong positive linear correlation between the total number of 
hydrogen bonds of both types that increases with the length of polyQ tract (Figure 4.12A), 
but the direction of the correlation dramatically changed to a negative relationship when 
considering the normalized count per 100 Qs (Figure 4.12B). This negative relationship is 
a very strong indication that the relative proportion of intra-polyQ hydrogen bonds 




Water solvent molecules can form bridges with glutamine residues in the polyQ tracts, 
and these bridges can affect folding and structure stability of polyQ tracts. Therefore, it 
may be expected that if polyQ tracts with different lengths have different solvent bridge 
patterns, their folding and structural integrity will also be affected. Figure 4.13 depicts the 
frequency of solvent-bridged glutamine pairs with the normalized residue distances. The 
bridges considered here are the ones that show in more than 100 time frames which 
correspond to at least 10% of the simulation time. We find that the frequencies of 
occurrence, for the observed bridges, range from 1% to 50%. Although the number of long-
ranged bridges is small among all three polyQ lengths considered here (Figure 4.13), 
polyQs with 32Q and 46Q repeats form more long-ranged bridges than the polyQ 


















Figure 4.12 Number of intra-polyQ hydrogen bonds vs. the number of solvent-polyQ 
hydrogen bond. A total count; B count normalized by number of repeats. The error bars 
are the standard deviation from all the MD simulations for each polyQ length. Red: Q18; 




















Figure 4.13 Distance distribution of observed solvent bridges lasting more than 100 frames 
in the simulation. The normalized distance is calculated as (|acceptor residue index-donor 




and 46Q polyQs, whereas only ~1.6% of the bridges are in long range in the 18Q polyQs. 
These results are consistent with the above discussion on the hydrogen bond results, both 
of which show a substantial decrease of solvent interactions and likely, more compact 
structures as the length of the polyQ tracts increases.  
 
Radius of Gyration (Rg) 
 
The Rg is used to describe the compactness of a protein. It is defined as the root mean 
square distance of the collection of atoms from their common center of gravity.  
For flexible polymers, the Rg value is proportional to Nb, where N is the length of the 
polymer [51] and b is characteristic of the solubility of the polymer. A good solvent is 
characterized by an exponent of ~ 0.59, as chain-solvent interactions are preferred, whereas 
a poor solvent has an exponent value of ~ 0.33, as the chain collapses to minimize contact 
with solvent [51] .Using the 105-ns simulation data, we find a value of b = 0.45 for the 
polyQ segments in water solution studied here (Figure 4.14). This indicates that there is a 
tendency to collapse among the polyQ structures as the length of the polyQ segment 
increases. Consistent with the results of previous sections in this paper, the results of Rg 
indicates that longer polyQ segments are less soluble, which is also consistent with an 
increase of their propensity to aggregation as the length of the polyQ increases. 
 
Solvent Accessible Surface Area (SASA) 
 
As expected, the total SASA of polyQ segments studied here increases as the number 
of polyQ length increases (Figure 4.15). Both total backbone and total sidechain SASA 
follow the same trend, but sidechain SASA increases faster than the backbone SASA. 


















Figure 4.14 Scaling laws for polyQ monomers in water. Black dots are the Rg values of 



















Figure 4.15 Solvent accessible surface area. A total SASA; B normalized SASA. Red: 






decreases with polyQ length (Figure 4.15), which is the same trend from what observed for 
the Rg values. The normalized backbone SASA for all polyQ sequences studied here is on 
average smaller than 20 Å2, therefore it is likely that polyQ backbone may be buried inside 
the structures rather than residing at the surface [52]. These results are also consistent with 
the results of previous sections, all of which indicate that the ability of polyQ monomers 




Consistent with the fact that the expansion of polyQ sequence beyond a certain 
threshold, specific for each polyQ disease, triggers pathogenesis [53], numerous 
observations have suggested that the polyQ tract by itself may play a central role in the 
pathogenesis of the ten known polyQ neurodegenerative diseases [13].  
In this study, three different lengths of polyQ segments are considered, Q18, Q32, and 
Q46, to cover normal, intermediate and pathological ranges relevant for most of the polyQ 
diseases. The full atomistic MD simulations with explicit solvent presented here show that 
all polyQ segments mainly form random-coiled structures, which is consistent with 
previous literature studies [20]. But the results in this study also show an increasing 
propensity to form helical and β structures as the number of glutamines increases in the 
polyQ tract. The type of β-structures are different among polyQ monomers of different 
lengths. The β-structures in Q46 are dominated by parallel β-structures, whereas for Q18 
and Q32, the majority are antiparallel β-structures. While Q18 and Q32 polyQ monomers 
can form parallel β-structures, these structures are not stable and cannot last till the end of 
the simulations (Figures 4.2 and 4.3). On the contrary, for Q46 the parallel β-structures, 





formation of a proto-structure conducive to aggregation. 
In this study, the MD simulations of polyQ segments in water predict a b scaling factor 
for the Rg of 0.45 indicating that water is not a good solvent for polyQ [54, 51]. Consistent 
with the results of Vitalis et al. [51], this result indicates the decreased preference of 
solvent-polyQ interaction as the number of repeats increases in polyQ monomers. This 
observation is also consistent with all the results, performed here, of the changes in 
hydrogen bond patterns as the lengths of the polyQ sequences increase. 
The results of the normalized SASA also support the idea that the preference of water-
polyQ interaction decreases as the length of polyQ increases. Although the total SASA is 
larger for polyQ monomers with longer repeats, the SASA per residue decreases as the 
repeat number of polyQ tract increases, especially for the sidechain surface area (Figure 
4.15).  
This study also explores the preference of the intra-polyQ vs. solvent-polyQ hydrogen 
bond formation, and the results show that the normalized number of hydrogen bonds per 
residue increases for the former and decreases for the latter type of hydrogen bond, as the 
number of repeats increases (Figure 4.5 and Figure 4.10). Q18, Q32, and Q46 can 
potentially form long-ranged hydrogen bonds. Considering the hydrogen bonds that show 
in more than 50% of the simulation time, in Q18 the majority of them are short-ranged 
ones with residues that are only 2- and 3-residue apart. However, long-ranged hydrogen 
bonds do exist in a larger proportion in Q46 (Figure 4.9). Driven by the long-distance 
interaction, polyQ sequences with longer lengths can fold into more compact structures, 
which also indicates an increasing propensity to avoid solvent interactions.  





hydrophobicity as the polyQ segments become longer. This raises the hypothesis that the 
pathogenic cause of the polyglutamine diseases may be rooted in the increased 
hydrophobicity of their polyQ tracts, which hydrophobicity, by increasing protein 
aggregation, causes neural degeneration. While results of this study does not provide direct 
evidence of the role which the polyQ segments play in polyglutamine protein aggregation, 
in the neurodegenerative diseases considered here, given the fact that the only common 
element of these diseases is the enlargement of polyQ segments in their associated proteins, 
the results presented here provide impetus to further exploring the hypothesis listed above. 
This study is not without limitations. Only polyQ monomers are studied and the inter-
molecular interactions among polyQ monomers, which can contribute to aggregation [55], 
are not included in this study. Additionally, regions flanking the polyQ tract are not 
considered in this study. Results of our previous study have demonstrated that regions 
flanking polyQ tracts alter polyQ secondary structure models [56], consistent with findings 
that these flanking regions alter aggregation of polyQ proteins [57, 29, 58]. However, with 
the existing study settings, it is easy for us to study the solvation of polyQ tract with the 




This paper studies the effect of solvation on the folding of polyQ segments with repeat 
lengths in the normal, intermediate, and pathological ranges using all-atom molecular 
dynamics simulations with an explicit water solvent environment. In accordance with the 
literature, the results of this study show that polyQ monomers can fold, but are disordered, 
when in water. GPU acceleration has effectively improved computational performance, 





with reasonable time. The simulations show that, as the length of a polyQ monomer 
increases, the water solubility of the polyQ segments decreases, while the propensity to 
form more compact structures with intra-polyQ hydrogen bonds increases. The results of 
this study demonstrate gains in aggregation propensity with increased polyQ lengths that 
correlates with decreasing ability of solvent-polyQ interaction. These results are consistent 
with previous observations using coarse-grained simulations, and suggest that modulation 
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HYDROGEN BONDING AND WATER ACCESSIBILITY OF THE 
 
POLYGLUTAMINE REGIONS IN ATAXIN-2 AND ATAXIN-3 
 





The hydrogen bondin and solvent accessibility of the polyglutamine (polyQ) chain may 
play an important role in polyQ protein aggregation, which has been postulated as a key 
factor in the pathogenesis pathway of at least ten neurodegenerative diseases. In a recent 
paper, using molecular dynamics simulations of isolated polyQ segments in explicit 
solvent, our previous study predicts an increase in aggregation propensity, due to 
increasing intra-polyQ hydrogen bonding capacity, as the length of the polyQ chain 
increases. Here, this study reports the hydrogen bonding and solvent accessibility changes 
of polyQ segments of increasing length, within the sequence-context of full-length ataxin-2 
and ataxin-3 3D structures predicted by I-TASSER. The results of this study show that, as 
the length of the polyQ region increases, there is a corresponding increase of intra-polyQ 
hydrogen bonding propensity. These results are consistent with our previous molecular 
dynamics simulations and support the hypothesis that polyQ hydrogen bonding self-
interactions increase with the lengths of polyQ chains, suggesting this increased self-
interaction capacity as a relevant cause of polyQ enlargement pathogenesis. These results 









The unstable expansion of the polyglutamine (polyQ) tract is associated with at least 
ten neurodegenerative diseases, including Huntington’s disease [1], dentatorubral-
pallidoluysian atrophy (DRPLA) [2], spinal and bulbar muscular atrophy (SBMA) [3], and 
seven spinocerebellar ataxias (SCA) type 1, 2, 3, 6, 7, 8, and 17 [4-7], all together, known 
as polyglutamine diseases [8]. The proteins underlying these diseases, termed as polyQ 
proteins, vary in sequence and function, whereas polyQ tract is the only common sequence 
element shared by the ten polyQ proteins [9]. The protein conformational misfolding and 
formation of intracellular aggregation are the hallmarks of polyQ diseases [10]. 
Solvent accessibility and hydrogen bonding are important factors for determining 
structural stability and aggregation in polyQ peptides. In a recent paper, using molecular 
dynamics (MD) simulations of isolated polyQ segments in explicit solvent, our previous 
study indicates that, as the length of the polyQ chain increases, there is an increase in 
aggregation propensity in polyQ tracts, due to increasing intra-polyQ hydrogen bonding 
capacity [Chapter 4]. The hydrogen bonding trend, as function of polyQ length, is also 
shown in other simulation studies of individual polyQ segments [11, 12]. Yet, very little is 
known about how these trends of the hydrogen bonding and solvent accessibility, in 
isolated polyQ segments, translate to the situation where the polyQ segment is embedded 
within a polyQ protein. The hydrogen bonding and solvent accessibility capacity of polyQ 
within the polyQ protein is a particularly important issue, as our previous computational 
studies show that the length of the polyQ tract can affect, not only the local, but also the 





Here, this study reports the changes in hydrogen bonding and solvent accessibility of 
polyQ segments with increasing polyQ lengths, within the sequence-context of full-length 
ataxin-2 and ataxin-3 proteins, using 3D structures predicted by I-TASSER [13]. Ataxin-2 
and ataxin-3 are selected for this study because they are two of the best characterized polyQ 




Protein 3D Structure Prediction  
 
An ensemble of ataxin-2 and ataxin-3 structures, predicted using the I-TASSER protein 
structure prediction package [16], are used for the analysis presented here. Both ataxin-2 
and ataxin-3 with polyQ regions of varying length are studied. For ataxin-2, the number of 
repeats of the polyQ segments considered here are 13, 22, and 31 as normal repeats, and 
32, 37, and 79 as pathogenic ones [17]. For ataxin-3, the normal repeat lengths considered 
are 27 and 36, the intermediate ones are 48 and 56, and the pathogenic ones are 64 and 75 
[18]. Sequences with a given number of glutamine repeats are named P-nQ, where P is 
either ataxin-2 or ataxin-3 and n is the number of repeats. The details of the structure 
prediction procedure and the predicted structures can be found in our previous publication 
[13].  
 
Hydrogen Bond Determination  
 
Hydrogen bond (HB) is inferred using UCFS Chimera [19] FindHBond module with a 
hydrogen donor-acceptor distance cutoff of 3.5 Å. Several types of HBs are identified here: 
HBs formed by residues within the polyQ region are defined as intra-polyQ HBs, whereas 





are called inter-polyQ HBs. The intra-polyQ HB can be further classified as backbone-
backbone HB, backbone-sidechain HB and sidechain-sidechain HB according to the amide 
groups in glutamine which participate in the hydrogen bond.  
 
Solvent Accessible Surface Area 
 
Solvent-accessible surface area (SASA) is the surface area of a biomolecule that is 
accessible to a solvent, and in this study it is used as a parameter to quantify the solvent 
accessibility of the polyQ peptide. The Dictionary of Protein Secondary Structure (DSSP) 
program [20] is used to calculate the absolute SASA of each residue in the predicted 
structures. The commonly accepted precutoff of 20 Å2 is used to determine whether the 




The Pearson product-moment correlation coefficient test is used with the significant 
level set at 0.05 in this study. All the statistic computing and graphics are generated using 




The polyQ regions in both ataxin-2 and ataxin-3 can form both intra-polyQ and inter-
polyQ HBs regardless of the number of repeats in the segment. As the number of glutamine 
repeats increases, the total number of HBs in the polyQ region also increases in both ataxin-
2 and ataxin-3 (Figure 5.1 (a) and (b)). However, when the total count of HBs is normalized 
by the number of glutamines in the polyQ region, this normalized HB count in ataxin-2 
slightly decreases with the number of repeats (Figure 5.1 (c)), whereas in atatxin-3, the 









Figure 5.1 Number of hydrogen bond in polyQ region. (a) absolute count of hydrogen bond 
in ataxin-2; (b) absolute count of hydrogen bond in ataxin-3; (c) normalized count of 
hydrogen bond in ataxin-2; (d) normalized count of hydrogen bond in ataxin-3. Red: total 
number of hydrogen bond in polyQ region; green: number of intra-polyQ hydrogen bond; 
and blue: number of inter-polyQ hydrogen bond. All the data is shown in mean value with 





(Figure 5.1 (d)). The increase of the count of intra-polyQ hydrogen bond is responsible for 
almost all the increase observed in the total number of HBs, with the inter-polyQ HBs 
count remaining constant. When normalized by the number of repeats in the polyQ region, 
the normalized count of intra-polyQ HBs increases with the number of repeats in both 
ataxin-2 and ataxin-3 (Figure 5.1 (c) and (d)), whereas the normalized count of inter-polyQ 
HBs decreases as the number of repeats increases in both ataxin-2 and ataxin-3 (Figure 5.1 
(c) and (d)).  
The count of sidechain intra-polyQ HBs are similar in ataxin-2 and ataxin-3 for polyQ 
tracts of similar sizes (Figure 5.2). Considering ataxin-2 and ataxin-3 together, when 
normalized - the count of sidechain HBs is divided by the number of glutamines of the 
polyQ region - the number of side-chain HBs per 100 glutamine increases with the number 
of repeats (Figure 5.2 (b), R2=0.425, p<0.001). A further analysis is conducted on the 
origins of the increase of the intra-polyQ HB, and results reveal that all considered 
categories, including backbone-backbone, backbone-sidechain, and sidechain-sidechain, 
contribute equally to the overall propensity of the polyQ segment to form intra-polyQ HBs, 
as the length of the segment increases. These results are a clear indication that as the 
number of repeats increases, the compactness of the polyQ segment increases.  
The absolute SASA of polyQ regions increases with the number of glutamines in the 
polyQ region; when considering all the data from ataxin-2 and ataxin-3 there is a 
correlation between the absolute SASA and the number of glutamines in the polyQ region 
(R2=0.83, p<0.001, (Figure 5.3 (a)). However, when the SASA of polyQ regions is 
normalized by the number of repeats, the normalized SASA per glutamine in ataxin-2 is 

















Figure 5.2 The number of sidechain intra-polyQ hydrogen bond. (a) absolute count of 
sidechain hydrogen bond; (b) normalized count of sidechain hydrogen bond. Blue: total 
sidechain hydrogen bond; red: sidechain-backbone hydrogen bond; green: sidechain-
sidechain hydrogen bond. All data are shown with mean value and standard deviation. The 
lines are used for display only. Data of ataxin-2 and ataxin-3 are combined together and 








Figure 5.3 Solvent accessible surface area of polyQ regions in ataxin-2 and ataxin-3. (a) 
total solvent accessible surface area of polyQ regions of ataxin-2 and ataxin-3; (b) 






SASA per glutamine decreases slightly with the number of repeats (Figure 5.3 (b) blue). 
When using a precutoff of 20 Å2 per-residue [21] to estimate the SASA for two water 
molecules, the number of residues in the polyQ region with a SASA value greater than 20 
Å2 shows the same trends as those for the total SASA in the polyQ tract (data not shown). 
Therefore, the calculated SASA properties consistently show that the relative area 
accessible to the solvent cannot increase as fast as the size of the polyQ segment increases. 
These results indicate the increasing compactness of the polyQ segment with increasing 
segment length and is consistent with the observation of the increased tendency to form 




Hydrogen bonding and solvent-protein interactions are key factors determining protein 
folding, stability, and aggregation. In our previous MD simulation study, the HBs and 
solvent-polyQ interaction of a polyQ monomer are studied in an explicit solvent 
environment. Our previous study finds that as the polyQ length increases, the polyQ tracts 
increasingly prefer self-interactions than solvent-polyQ interactions [Chapter 4]. The 
aforementioned study was restricted to single polyQ segment, therefore question arises, 
how transferable are the MD results to situations in which the polyQ segment is embedded 
in a protein? Unfortunately, MD simulations of entire polyQ disease proteins in explicit 
solvent are unfeasible, therefore this study analyzes the HB and solvent accessibility 
patterns of the 3D structures of polyQ segments within full-length ataxin-2 and ataxin-3, 
from our previous work [13].  
In all 3D structures analyzed here, the total number of HBs observed in the polyQ 





normalized count of intra-polyQ HBs increases with the polyQ length, whereas the 
normalized count of inter-polyQ HBs decreases with the polyQ length. This HB trends are 
consistent with our MD simulation findings, showing that polyQ regions increasingly 
prefer self-interactions as the length of the polyQ segment increases. The solvent 
accessibility properties of the polyQ regions also share common trends, regardless of the 
host proteins. Although the total SASA of polyQ regions increases with the polyQ lengths, 
its normalized values decrease with the polyQ lengths. The SASA properties are consistent 
with both the HB results and SASA results of our previous MD simulations. These results 
strongly suggest that the increase of the length of the polyQ segments leads to an increase 
in the compactness of these segments, which increased compactness is independent of 
protein environment. Moreover, as the structures of the polyQ regions are different for 
ataxin-2 and ataxin-3 – random coil in ataxin-2 and α-helix in ataxin-3 [13] – the increased 
preference to adopt intra-polyQ HBs upon polyQ length enlargement appears to be an 
intrinsic properties of polyQ, which increase does not depend on secondary structure. 
Evidence shows that most of the aggregation-prone structures of polyQ peptides are 
antiparallel β-strands and β-helical structures, which are stabilized by an extensive network 
of HBs between glutamines in the polyQ regions [23-26]. Therefore an increase of intra-
polyQ HBs will increase the probability of the formation of aggregation-prone structures 
in the polyQ segments.  
Using H/D exchange technology, Natalello et al. find that polyQ sidechain HBs are 
strongly involved in the formation of mature amyloid aggregates in ataxin-3-55Q, and the 
formation of sidechain HBs is the hallmark of mature fibrils generated by ataxin-3 with 





glutamine in the polyQ segments is positively correlated with the number of repeats in the 
polyQ segments. This correlation provides additional support for our argument that the 
increase of the polyQ length is conducive to polyQ aggregation. Wang et al. indicate [12] 
that glutamine sidechains can compete with water in forming HBs with the glutamine 
backbone, therefore an increase of the propensity of forming sidechain HBs with the 
backbone, as observed here, could decrease the ability to solvate the backbone and 




Using predicted 3D structures of ataxin-2 and ataxin-3 with polyQ segments of 
increasing length, we are able to study the changes in hydrogen bonding and solvent 
accessibility of polyQ regions within the sequence context of two well characterized polyQ 
proteins. Our results strongly suggest that the HB and solvent accessibility properties of 
the polyQ regions have an intrinsic dependency on the length of the polyQ segment, 
regardless of the protein host. The results presented here are consistent with previous 
studies, including our own molecular dynamics (MD) study on polyQ monomers in explicit 
solvent, and indicate that polyQ regions increasingly prefer self-interactions, which 
consistently can lead to more compact polyQ structures. The results also strongly support 
the notion that the enlargement of the polyQ regions can be the intrinsic force leading to 
self-aggregation of polyQ proteins, making polyQ aggregation the leading mechanisms in 
the pathogenesis pathway of polyQ diseases. The results of this study suggest the 
modulation of solvent-polyQ interaction as a possible therapeutic strategy for the treatment 
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DISCUSSION AND CONCLUSION 
 
 
Summary of Important Findings 
 
By using computational and informatics methods, this dissertation is able to study the 
structural and folding characteristics of both polyQ proteins and polyQ monomers. The 
results of this dissertation bring insights into the molecular mechanisms of polyQ 
aggregation and the pathogenesis of polyQ diseases. 
Protein 3D structure prediction is a powerful tool for biomedical research. However, it 
is necessary to evaluate the prediction performance of these methods on polyQ proteins 
before large scale predictions are done. In Chapter 2, two of the best-performing protein 
3D structure prediction programs, I-TASSER [1] and Rosetta [2], are tested on their 
prediction performance of the N-terminal huntingtin protein with 17 glutamines (HTT-
17Q). Both I-TASSER and Rosetta perform well at predicting the structure of HTT-17Q 
determined by comparing the predicted models with the X-ray crystal structures of HTT-
17Q [3]. Yet I-TASSER performs better than Rosetta, as the I-TASSER models show better 
agreement on the overall structures of the X-ray structures of HTT-17Q than Rosetta dose 
and I-TASSER models also better represent the diversity of secondary structures in the 
polyQ regions.  
As a next step, I-TASSER is used to predict the 3D structures of ataxin-2 and ataxin-3 





tracts in both normal and pathogenic ranges are studied. In Chapter 3, the structure and 
conformation changes are described as the function of the length of polyQ tract, while the 
water accessibility and hydrogen bonding changes are discussed in Chapter 5.  
I-TASSER models of ataxin-2 and ataxin-3 indicate that the enlargement of the polyQ 
tract can affect not only the local structures of polyQ tracts but also the global structures of 
polyQ proteins. As the lengths of polyQ tracts increase, the proportion of helical structures 
increases in both ataxin-2 and ataxin-3. The elongation of the polyQ tract can also affect 
the structure of functional domains in ataxin-2 and ataxin-3 [4]. For example, the UIM1-2 
domains in ataxin-3 adopt helix-coil-helix structures, which are required for normal 
functions [5]. However, the flexible structures are lost in some of the ataxin-3 models with 
pathogenic polyQ tracts. These results indicate that the polyQ tract can lead to the 
dysfunction of polyQ proteins by changing the structures of their functional domains. Also, 
the changes in both local and global structures suggest that the study of full-length polyQ 
proteins is necessary to get a comprehensive understanding of the pathogenic mechanisms.  
In addition to polyQ proteins, the folding dynamics and the solvent-polyQ interactions 
of polyQ monomers are studied using molecular dynamics (MD) simulation (Chapter 4). 
PolyQ lengths in the normal, intermediate, and pathogenic ranges are studied. Using GPU-
acceleration, it is possible to conduct 105-ns all-atom MD simulations in an explicit solvent 
environment within a reasonable time frame. The MD simulation results show that, as the 
lengths of the polyQ segments increase, the polyQ tracts increasingly prefer adopting intra-
polyQ hydrogen bonds than adopting solvent-polyQ hydrogen bonds. Long-distance 
interactions between residues far apart in polyQ are more predominant in long-polyQ 





study demonstrates gains in aggregation propensity with increased polyQ length, and 
suggests that the modulation of solvent-polyQ interaction may be a possible therapeutic 
strategy for the treatment of polyQ diseases.  
Using the full-length 3D structure models of ataxin-2 and ataxin-3 predicted by I-
TASSER, Chapter 5 explores the hydrogen bonding and water accessibility of polyQ tracts 
within the context of the polyQ proteins, similar results are get as those shown in polyQ 
monomers using MD simulations (Chapter 4). The results, from the full-length ataxin-2 
and ataxin-3 structures, show an increased preference in adopting intra-polyQ hydrogen 
bonds as the length of polyQ region increases, whereas the preference to forming inter-
polyQ hydrogen bonds decreases with the length of the polyQ tract. The absolute SASA 
values of polyQ regions increase with the number of glutamine repeats in ataxin-2 and 
ataxin-3, but the normalized SASA values decrease with the polyQ length. These results 
again indicate that, as the length of polyQ increases, the polyQ self-interaction increases 
and the propensity of aggregation increases. 
As a protein involved in RNA processing pathway [6], ataxin-2 is a component of stress 
granules [7] which are dense aggregations composed of proteins and RNAs [8]. The stress 
granules appear when the cell is under stress and it is a mechanism to protect RNAs from 
reacting with harmful compounds. Stress granules exhibit non-membrane liquid properties 
[8]. Recent studies show that the low complexity domains in the stress-granular proteins 
play a role in inducing a liquid phase transition through inter-molecule interactions [9, 10]. 
The predicted 3D structures of ataxin-2 proteins show low complexity, with a structural 
dominance of random coils in this study [4], therefore these flexible conformations could 





granules. The structure and solvent accessibility changes in ataxin-2, induced by the 
enlargement of polyQ tract, might also affect the structure and normal function of stress 
granules in several possible ways. The structural changes of the functional domains in 
ataxin-2, induced by the enlargement of polyQ tract, might also change the proteome in the 
stress granules, by altering the protein-protein interactions. This hypothesis is supported 
by the results of Jain et al. which show that ATPase-modulated stress granules contain a 
diverse proteome [11]. The changes of proteome in the stress granules might alter the 
dynamic equilibrium of the ribonucleoprotein in the cell. Jain et al. also find that stress 
granules contain a stable substructure core [11]. The changes of the interaction partners 
might also change the stability and conformation of the core. Also the increase of self-
interaction in polyQ regions might affect the phase transition of stress granules between 
monomer, liquid droplet, and hydrogel states. This is also consistent with the results of 
Murakami et al. that found that mutations in low-complexity domain of FUS gene, a gene 
related with neurodegenerative disease ALS, affect the phase transition of stress granules 
and accelerate transition into fibrillary hydrogens, which will cause neurodegeneration 
[12]. As the increase of self-interaction in polyQ regions could lead to more compact 
structures of polyQ and induce self-aggregation, pathogenic polyQ segments might also 
induce further phase transitions into irreversible fibrillary structures. All these possible 
changes in the function and structure in stress granules might affect the RNA and protein 
microenvironment of the cells and might impair granule functions. Further experimental 
and coarse grain studies are needed to explore the proteome and structures of the stress 
granules in which ataxin-2 with different polyQ lengths are involved.  





better understand the polyQ length-dependent aggregation pathogenic mechanisms, and 
suggest possible treatment strategies for polyQ diseases.  
 
Contribution to Biomedical Informatics 
 
This study provides an effective informatics solution and workflow to study the 
pathogenic mechanism of polyQ diseases at the protein level, and proves that 
computational and informatics methods are powerful and effective tools to study polyQ 
diseases. Several informatics methods are created or modified from the existing methods, 
providing better analysis and visualization of the results. For example, the WebLogo [13], 
which was originally created for gene/protein sequence comparison, is used as a tool to 
show secondary structure patterns in this study, and provides a powerful tool for secondary 
structure visualization and comparison. Also the structure similarity scores are created for 
a quantitative comparison of the structure similarity in the polyQ regions [3]. 
The computing time and efficiency are critical factors that limit the application of 
computational work in the biomedical field. In this study, some state-of-the-art high 
performance computing technology, such as parallel computing and GPU acceleration, are 
applied to increase the computational efficiency, which makes it possible to generate all 
the structural data within a reasonable time frame. 
The workflow provided by this dissertation can be easily generalized to study other 
protein conformation related diseases, including Parkinson’s disease, Alzheimer's disease, 
and even cancer. At this point, the workflow is successfully applied to study a rare nonsense 
mutation in cutaneous malignant melanoma and the computational explanation of the 
pathogenesis of this mutation is consistent with results from experimental studies (results 
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